Download CINP App to access the 2019 CINP International Meeting App

How to download

» Scan one of these barcodes.
» Search ‘CINP’ in the Apple App or Google Play Store.
Esteemed colleagues,

Welcome to the CINP 2019 International Meeting on *Breakthroughs and Controversies in Mood, Psychosis, Schizophrenia, ADHD, and Insomnia*.

It is our great pleasure to have you with us here in the noble and historic city of Athens, Greece.

As promised, the programme of the CINP 2019 International Meeting expands on the 2017 Prague meeting, as well as on aspects from our 2018 Vienna Congress, and we have taken great care to develop the programme to bring you the newest developments in the wider fields of psychiatry and psychopharmacology.

We are proud to see a great number of delegates from all corners of the world, with a particular emphasis on delegates from the Southern European region. The diversity of our delegates again showcases the immense range of skills, backgrounds and fields of work of our membership around the world. It is indeed a true pleasure to witness the coming together of such a truly international group of professionals, sharing their knowledge and exchanging new ideas.

Personally, as the current CINP President, I am certain that I speak on behalf of the entire leadership of CINP that we hope you will get the most out of this meeting for yourselves, your organisations and your work from this meeting. We do very much encourage you to share your ideas and engage both on-site as well as online with each other and with us, as friends and colleagues, to continue building our international community, move forward the research and education of psychopharmacology and increase our professional interaction.

Please enjoy Athens, enjoy the CINP 2019 International Meeting, and – very importantly – yourselves. I look forward to meeting with as many of you as possible during the coming days.

Professor
Siegfried Kasper
President of CINP
(2018 – 2020)
<table>
<thead>
<tr>
<th>Time</th>
<th>Thursday 3 October</th>
<th>Friday 4 October</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00</td>
<td></td>
<td>08:00</td>
</tr>
<tr>
<td>08:30</td>
<td><strong>08:30 - 10:00 Welcome &amp; Keynote Lecture</strong></td>
<td><strong>09:00 - 10:00 Oldrich Vinar Keynote Lecture</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Rapid acting antidepressants: Opportunities and mechanisms John H. Krystal</strong></td>
<td><strong>Treatment resistant depression Siegfried Kasper</strong></td>
</tr>
<tr>
<td>10:00</td>
<td><strong>10:00 - 10:30 Coffee Break / Showcase Presentation by Sage</strong></td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td><strong>10:30 - 12:00 Symposium Breakthroughs and controversies in mood disorders</strong></td>
<td><strong>10:30 - 12:00 Symposium Breakthroughs and controversies in ADHD</strong></td>
</tr>
<tr>
<td></td>
<td>Frances Artigas, Alessandro Serretti, Carlos Zarate</td>
<td>Zheng Chang, Larry Klassen, Andrea Cipriani</td>
</tr>
<tr>
<td>11:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td><strong>11:30 - 12:00 Lunch / Poster Viewing</strong></td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td><strong>13:00 - 14:30 Symposium Breakthroughs and controversies in psychosis</strong></td>
<td><strong>13:30 - 14:30 Keynote Lecture</strong></td>
</tr>
<tr>
<td></td>
<td>Carol Tamminga, Konstantinos Fountoulakis, Shih-Ku Lin</td>
<td><strong>Antidepressants work: The evidence Elias Eriksson</strong></td>
</tr>
<tr>
<td>13:30</td>
<td><strong>13:30 - 14:30 Meet the Expert Presented by Janssen</strong></td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:30</td>
<td><strong>14:30 - 15:30 Keynote Lecture</strong></td>
<td><strong>14:30 - 16:00 Symposium Breakthroughs and controversies in insomnia</strong></td>
</tr>
<tr>
<td></td>
<td><strong>The future of manualized versus personalized psychiatry Tarek Okasha</strong></td>
<td>Andrew Krystal, Pierre Michel Llorca, Gabriella Gobbi</td>
</tr>
<tr>
<td>15:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30</td>
<td><strong>15:30 - 16:00 Coffee Break / Showcase Presentation by Saladax Biomedical</strong></td>
<td><strong>14:30 - 16:00 Meet the Expert Larry Klassen</strong></td>
</tr>
<tr>
<td>16:00</td>
<td></td>
<td><strong>14:30 - 16:00 Workshop For Young Clinicians Pierre Blier</strong></td>
</tr>
<tr>
<td>16:30</td>
<td><strong>16:00 - 17:30 Symposium Pharmacological augmentation in treatment resistant mental disorders Organised by the Hellenic Psychiatric Association</strong></td>
<td><strong>16:30 - 17:30 Keynote Lecture Neuroactive steroids as rapid-acting antidepressants: The story of brexanolone and SAGE-217 Stephen Kanes</strong></td>
</tr>
<tr>
<td>17:30</td>
<td><strong>17:30 - 18:30 Guided Poster Session</strong></td>
<td><strong>17:30 - 18:30 Guided Poster Session</strong></td>
</tr>
<tr>
<td>18:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20:00</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## Saturday 5 October

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00</td>
<td></td>
</tr>
<tr>
<td>08:30</td>
<td></td>
</tr>
<tr>
<td>09:00</td>
<td><strong>09:00 - 10:00 Alec Coppen Keynote Lecture</strong></td>
</tr>
<tr>
<td></td>
<td><em>Interactions between neurotransmitters: The key to remission in depression</em> Pierre Blier</td>
</tr>
<tr>
<td>09:30</td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td><strong>10:00 - 10:30 Coffee Break</strong></td>
</tr>
<tr>
<td>10:30</td>
<td><strong>10:30 - 12:00 Symposium</strong></td>
</tr>
<tr>
<td></td>
<td><em>Future directions to understand psychiatric diseases</em></td>
</tr>
<tr>
<td></td>
<td>Konstantinos Pastiadis, Georgia Salanti, Hans-Jürgen Möller</td>
</tr>
<tr>
<td>11:00</td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td><strong>10:30 - 12:00 Workshop</strong></td>
</tr>
<tr>
<td></td>
<td>Erich Seifritz</td>
</tr>
<tr>
<td>12:00</td>
<td><strong>10:00 - 12:00 Meet the Expert</strong></td>
</tr>
<tr>
<td></td>
<td>Presented by Takeda</td>
</tr>
<tr>
<td>12:30</td>
<td><strong>12:00 - 13:00 Keynote Lecture</strong></td>
</tr>
<tr>
<td></td>
<td><em>New pharmacological treatments for resistant depression</em></td>
</tr>
<tr>
<td></td>
<td>Maurizio Fava</td>
</tr>
<tr>
<td>13:00</td>
<td><strong>13:00 - 13:30 Closing</strong></td>
</tr>
<tr>
<td>13:30</td>
<td><strong>13:30 – 14:30 Lunch</strong></td>
</tr>
<tr>
<td>14:00</td>
<td></td>
</tr>
<tr>
<td>14:30</td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td></td>
</tr>
<tr>
<td>15:30</td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td></td>
</tr>
<tr>
<td>16:30</td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td></td>
</tr>
<tr>
<td>17:30</td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td></td>
</tr>
<tr>
<td>18:30</td>
<td></td>
</tr>
<tr>
<td>19:00</td>
<td></td>
</tr>
<tr>
<td>19:30</td>
<td></td>
</tr>
<tr>
<td>20:00</td>
<td></td>
</tr>
</tbody>
</table>
The International College of Neuropsychopharmacology (CINP) is a truly worldwide organization established over 50 years ago in Zurich, Switzerland. CINP hold meetings all over the world with the aim to promote research and education on a worldwide basis. With the change to go annual with the CINP World Congress, the college will also focus more on smaller seminars and workshops in between.

The Executive Committee and Councilors of CINP are nominated by the membership and serve as an officer of the College for a minimum of 4 years. These individuals cover a wide range of disciplines within the field, from psychiatrists, psychopharmacologists, basic and clinical researchers to clinical psychologists. CINP also relies on its many subcommittees who undertake a variety of activities for the College.

Membership of the College is available to any individual to apply for and we offer members the opportunity to become part of this knowledgeable group of scientists who work at an international level. The membership application is reviewed by a dedicated committee on a regular basis and applications can be made online. As a member of CINP you may have the opportunity to be invited to one of the smaller meetings or invited to participate in the running of the College by sitting on a subcommittee.

Oxford University Press has a rich history dating back to 1478; today OUP has 6,000 employees in offices in 50 countries and is the largest university press in the world. OUP has an incredibly diverse publishing program; publishing in more than 40 languages and in a variety of formats—print and digital, for all audiences—from pre-school to secondary level schoolchildren; students to academics; general readers to researchers and clinicians; individuals to institutions. As a department of the University of Oxford, our worldwide publishing furthers the University’s objectives of excellence in scholarship, research, and education.

For more information about the College visit www.cinp.org
# CINP 2019 Committees

## Executive Committee

**CINP President**  
Kasper, Siegfried, Austria

**CINP Past President**  
Krystal, John H., USA

**CINP President Elect**  
Blier, Pierre, Canada

**CINP Vice President**  
Lin, Shih-Ku, Taiwan

**CINP Vice President**  
Zohar, Joseph, Israel

**CINP Secretary**  
Eriksson, Elias, Sweden

**CINP Treasurer**  
Ikeda, Kazutaka, Japan

## Councillors

Calil, Helena, Brazil  
Domschke, Katharina, Germany  
Falkai, Peter, Germany  
Fava, Maurizio, USA  
Gobbi, Gabriella, Canada  
Hashimoto, Ryota, Japan  
Kwon, Jun Soo, Republic of Korea  
Nitta, Atsumi, Japan  
Tamminga, Carol, USA  
Young, Allan, United Kingdom

## International Scientific Programme Committee

**Chair**  
Blier, Pierre, Canada

**Co-chair**  
Eriksson, Elias, Sweden

**Co-chair**  
Osumi, Noriko, Japan

Chiou, Lih-Chu, Taiwan

Cryan, John, Ireland

Domschke, Katharina, Germany

Falkai, Peter, Germany

Fountoulakis, Kostas, Greece

Frazer, Alan, USA

Gobbi, Gabriella, Canada

Huang, Ming-Chyi, Taiwan

Hiroi, Noboru, USA

Ikeda, Kazutaka, Japan

Kasper, Siegfried, Austria

Kwon, Jun Soo, Korea

Krystal, John, USA

Lanzenberger, Rupert, Austria

Lin, Shih-Ku, Taiwan

McGuire, Philip, UK

Morilak, David, USA

Shamay-Tsoory, Simone, Israel

Soldatos, Constantini, Greece

Tamminga, Carol, USA

Uchida, Hiroyuki, Japan

Yamawaki, Shigeto, Japan

Zohar, Joseph, Israel

## South-Eastern European Committee

Distinguished representatives from the following countries:

Albania  
Algeria  
Azerbaijan  
Bulgaria  
Burma  
Croatia  
Egypt  
Georgia  
Israel  
Lebanon  
Morocco  
North Macedonia  
Romania  
Russia  
Serbia  
Slovenia  
Tunisia  
Turkey  
Ukraine

## Local Organising Committee

**Chair**  
Fountoulakis, Kostas

Alevizopoulos, George, Greece

Alevizos, Basil, Greece

Christodoulou, George, Greece

Chrousos, George, Greece

Diakogiannis, Ioannis, Greece

Dikeos, Dimitris, Greece

Douzenis, Athanasios, Greece

Gourzis, Filippos, Greece

Hyphantis, Thomas, Greece

Mavreas, Venos, Greece

Michopoulos, George, Greece

Nimatoudis, Ioannis, Greece

Papageorgiou, Charalampos, Greece

Ploumpidis, Dimitrios, Greece

Samakouri, Maria, Greece

Siouti, Eirini, Greece

Skapinakis, Petros, Greece

Smyrnis, Nikolaos, Greece

Stefanis, Nick, Greece

Touloumis, Babis, Greece

Tsopelas, Christos, Greece

Vorvolakos, Theofanis, Greece

---

cinp2019.org | cinp2019@cinp.org
08:30 – 09:00 | Room: Olympia Hall

Welcome
Siegfried Kasper, CINP President
Konstantinos Fountoulakis, CINP 2019 Local Organising Chair
Constantin Soldatos, Honorary President of the World Federation of Societies of Biological Psychiatry
George Christodoulou, Honorary President of the Hellenic Psychiatric Association and President of the Society of Preventive Psychiatry

09:00 – 10:00 | Room: Olympia Hall

KL01 KEYNOTE LECTURE
Chair: Siegfried Kasper, Austria and Konstantinos Fountoulakis, Greece

Rapid acting antidepressants: Opportunities and mechanisms
John H. Krystal, USA

10:00 – 10:15 | Room: Olympia Foyer
Coffee Break

10:00 – 10:30 | Room: Olympia Foyer
SHOWCASE
Presented by Sage Therapeutics
How do you approach the treatment of depressive episodes today? What pathways are thought to play a role in depression?
Celso Arango, Spain

10:30 - 12:00 | Room: Olympia Hall

S01 SYMPOSIUM
Chair: Carlos Zarate, USA and Giorgos Alevizopoulos, Greece

Breakthroughs and controversies in mood disorders
10:30 - 10:55
S01.1 Mechanisms of antidepressant response
Francesc Artigas, Spain
11:00 – 12:25
S01.2 Genetics of antidepressant response
Alessandro Serretti, Italy
11:30 – 12:00
S01.3 Rapid acting antidepressants
Carlos Zarate, USA

10:30 - 12:00 | Room: Attica Hall

MTE01 MEET THE EXPERT
Chair: Georgia Salanti, Switzerland and Ioannis Michopoulos, Greece

60 years of antidepressants – where are we now?
Alan Frazer, USA

12:00 - 13:00 | Room: Olympia Foyer
Lunch / Poster Viewing

10:30 - 12:00 | Room: Templar’s Hall

YSF01 YOUNG SCIENTIST FORUM
Chair: Elias Eriksson, Sweden and Agorastos Agorastos, Greece

How to get your career on track early
YSF01.1 Getting published in competitive journals: Advice to the young investigator
John H. Krystal, USA

YSF01.2
Joseph Zohar, Israel
Scientific Programme

Thursday 3 October

13:00 - 14:30 | Room: Olympia Hall

S02 SYMPOSIUM

Chair: Carol Tamminga, USA and Nikos Stefanis, Greece

Breakthroughs and controversies in psychosis
13:00 – 13:25
S02.1 New antipsychotic drugs
Carol Tamminga, USA

13:30 – 13:55
S02.2 Controversies in literature in antipsychotic treatment
Konstantinos Fountoulakis, Greece

14:00 – 14:25
S02.3 Antipsychotic polypharmacy: Is it a dirty little secret or a fashion?
Shih-Ku Lin, Taiwan

13:00 - 14:30 | Room: Attica Hall

MTE02 MEET THE EXPERT

Presented by Janssen

Time to act in major depressive disorder (MDD)
13:00 - 13:05
Welcome & Introduction
Chair: Siegfried Kasper, Austria

13:05 - 13:45
When to act: Optimising treatment in MDD
Daniel Souery, Belgium
Andreas Papadopoulos, UK

13:45 - 14:25
How to act: Are fast-acting treatments the future?
Lucie Bartova, Austria
Andrew J. Cutler, USA

14:25 - 14:30
Close
Chair: Siegfried Kasper, Austria

13:00 - 14:30 | Room: Templar’s Hall

WS01 WORKSHOP
ORGANISED BY NIH / NIMH

Chair: Alan Frazer, USA and Athanasios Douzenis, Greece

Neurobiological and clinical characterization approaches for developing novel therapeutics for treatment-resistant depression
13:00 - 13:15
WS01.1 Towards clinical applications of fMRI - replicating global brain connectivity in treatment resistant depression
Christoph Kraus, USA

13:20 - 13:35
WS01.2 Developing imaging markers of depression and treatment response
Jennifer Evans, USA

13:40 - 13:55
WS01.3 Identification of neuroinflammatory markers via metabolomic profiling of a ketamine or placebo crossover trial in patients with treatment-resistant mood disorders
Bashkim Kadriu, USA

14:00 - 14:15
WS01.4 Development of next generation seizure therapy for treatment resistant depression
Zhi-De Deng, USA

14:20 - 14:30
WS01.5 Synopsis and outlook in developments
Discussant: Carlos Zarate, USA

14:30 – 15:30 | Room: Olympia Hall

KL02 KEYNOTE LECTURE

Chair: Shih-Ku Lin, Taiwan and Constantin Soldatos, Greece

The future of manualized versus personalized psychiatry
Tarek Okasha, Egypt

15:30 – 16:00 | Room: Olympia Foyer

Coffee Break
15:35 - 15:50 | Room: Olympia Foyer

SHOWCASE

Presented by Saladax Biomedical

Antipsychotic POCT for medication adherence and blood level monitoring

David Taylor, UK

16:00 - 17:30 | Room: Olympia Hall

S03 SYMPOSIUM ORGANISED BY THE HELLENIC PSYCHIATRIC ASSOCIATION

Chair: Charalampos Touloumis, Greece and Christos Tsopelas, Greece

Pharmacological augmentation in treatment resistant mental disorders

16:00 – 16:25
S03.1 Add-on treatment in schizophrenia spectrum disorders
Charalampos Touloumis, Greece

16:30 – 16:55
S03.2 Add-on treatment in treatment resistant depression
Christos Tsopelas, Greece and Maria Dimitraka, Greece

17:00 – 17:25
S03.3 Clinical challenges in dual diagnosis patients
Georgios Tzeferakos, Greece

17:30 – 18:30 | Room: Olympia Foyer

PS01 GUIDED POSTER SESSION

Chairs: Elias Eriksson, Sweden, Joseph Zohar, Israel and Pierre Blier, Canada
09:00 – 10:00  |  Room: Olympia Hall

**KL03 OLDRICH VINAR KEYNOTE LECTURE**
*Chairs: Hans-Jürgen Möller, Germany and Dimitris Dikeos, Greece*

**Treatment resistant depression**
*Siegfried Kasper, Austria*

10:00 - 10:10  |  Room: Olympia Hall

**Rafaelsen Young Investigators Awards**
*Presented by Siegfried Kasper, CINP President*

10:10 - 10:30  |  Room: Olympia Foyer

**Coffee Break**

10:30 - 12:00  |  Room: Olympia Hall

**S04 SYMPOSIUM**
*Chair: Larry Klassen, Canada and Eva-Maria Tsapakis, Greece*

**Breakthroughs and controversies in ADHD**

10:30 – 10:55
**S04.1 Treatment of ADHD: A pharmacoepidemiological approach**
*Zheng Chang, Sweden*

11:00 – 11:25
**S04.2 ADHD Treatment in adults**
*Larry Klassen, Canada*

11:30 – 11:55
**S04.3 Meta-analysis in ADHD response**
*Andrea Cipriani, UK*

10:30 - 12:00  |  Room: Attica Hall

**MTE03 MEET THE EXPERT**
*Chair: Jennifer Evans, USA and Dimitris Dikeos, Greece*

**Bipolar disorder – the CINP approach**
*Konstantinos Fountoulakis, Greece*

10:30 - 12:00  |  Templar’s Hall

**WS02 WORKSHOP**
*Chair: Andrew Krystal, USA and Maria Samakouri, Greece*

**Neuroscience-based nomenclature for psychotropic agents**
*Joseph Zohar, Israel*
*Pierre Blier, Canada*
*Hans-Jürgen Möller, Germany*

12:00 - 13:30  |  Room: Olympia Foyer

**Lunch / Poster Viewing**

13:30 - 14:30  |  Room: Olympia Hall

**KL04 KEYNOTE LECTURE**
*Chairs: Pierre Blier, Canada and Nikos Stefanis, Greece*

**Antidepressants work: The evidence**
*Elias Eriksson, Sweden*
## Scientific Programme

### Friday 4 October

**14:30 - 16:00 | Room: Olympia Hall**

**S05 SYMPOSIUM**

*Chair: Gabriella Gobbi, Canada and Theofanis Vorvolakos, Greece*

**Breakthroughs and controversies in insomnia**

14:30 – 14:55

S05.1 Orexin receptor antagonists: State of the art  
**Andrew Krystal**, San Francisco, USA

15:00 – 15:25

S05.2 Benzodiazepines pro and contra  
**Pierre Michel Llorca**, France

15:30 – 15:55

S05.3 Selective melatonin MT2 receptor agonists for the treatment of sleep disorders  
**Gabriella Gobbi**, Canada

**14:30 - 16:00 | Room: Attica Hall**

**MTE04 MEET THE EXPERT**

*Chair: Alessandro Serretti, Italy and Ioannis Nimatoudis, Greece*

**ADHD**  
**Larry Klassen**, Canada

**14:30 - 16:00 | Templar’s Hall**

**WS03 WORKSHOP FOR YOUNG CLINICIANS**

*Chair: Dietmar Winkler, and Athanasios Douzenis, Greece*

**Rational prescribing**  
**Pierre Blier**, Canada

**16:00 - 16:30 | Room: Olympia Foyer**

**Coffee Break**

**16:10 – 16:25 | Room: Olympia Hall**

**SHOWCASE**

*Presented by Janssen*

**Optimising treatment outcomes in major depressive disorder (MDD)**

16:10 - 16:13

Characterisation of the MDD patient  
**Lucie Bartova**, Austria

16:13 - 16:20

Current challenges of when and how to treat  
**Lucie Bartova**, Austria

16:20 - 16:25

Moderated Q&A session  
**Siegfried Kasper**, Austria

**16:30 – 17:30 | Room: Olympia Hall**

**KL05 KEYNOTE LECTURE**

*Chairs: John H. Krystal, USA and Ioannis Michopoulos, Greece*

**Neuroactive steroids as rapid-acting antidepressants: The story of brexanolone and SAGE-217**  
**Stephen Kanes**, USA

**17:30 – 18:30 | Room: Olympia Foyer**

**PS01 GUIDED POSTER SESSION**

*Chairs: Konstantinos Fountoulakis, Greece, Gabriella Gobbi, Canada, Francesc Artigas, Spain and Agorastos Agorastos, Greece*
09:00 – 10:00 | Room: Olympia Hall

KL06 ALEC COPPEN KEYNOTE LECTURE

Chair: Maurizio Fava, USA

Interactions between neurotransmitters: The key to remission in depression
Pierre Blier, Canada

10:00 - 10:30 | Room: Olympia Foyer

Coffee Break

10:30 - 12:00 | Room: Olympia Hall

S06 SYMPOSIUM

Chair: Pierre Michel Llorca, France and Nikos Stefanis, Greece

Future directions to understand psychiatric diseases

10:30 - 10:55

S06.1 Digital psychopharmacology
Konstantinos Pastiadis, Greece

11:00 – 11:25

S06.2 New findings from old studies: Insights into the evidence of efficacy, tolerability and acceptability of antidepressants
Georgia Salanti, Switzerland

11:30 – 11:55

S06.3 Evidence does not equal evidence
Hans-Jürgen Möller, Germany

10:30 - 12:00 | Room: Attica Hall

WS04 WORKSHOP

Chair: Joseph Zohar, Israel and Athanasios Douzenis, Greece

Depression – new treatments with psychedelics
Erich Seifritz, Psychiatrische Universitätsklinik Zürich, Switzerland

10:00 - 12:00 | Room: Templar’s Hall

MTE05 MEET THE EXPERT

Presented by Takeda

Discovering ADHD in adults
Susan J. Young, UK
Larry Klassen, Canada
Josep Antoni Ramos-Quiroga, Spain

12:00 - 13:00 | Room: Olympia Hall

KL07 KEYNOTE LECTURE

Chair: Erich Seifritz, Switzerland

New pharmacological treatments for resistant depression
Maurizio Fava, USA

13:00 - 13:30 | Room: Olympia Hall

Closing Session

13:30 – 14:30 | Room: Olympia Foyer

Lunch
Ole Rafaelsen and William Bunney were instrumental in establishing a CINP programme supporting the attendance of young scientists at the XV CINP Congress in 1986. That programme was posthumously named the Rafaelsen Fellowship Award to honour Dr. Rafaelsen, who died in 1987. The Rafaelsen travel awards enable young researchers to attend the 2019 CINP International Meeting in Athens and mark a step in a future rising career. The recipients of the awards are chosen by an international scientific jury. The selected recipients also have the opportunity to present their poster as part of the scientific programme.

2019 CINP Rafaelsen Awardees

Zheng Chang

Zheng Chang is an assistant professor at the Department of Medical Epidemiology and Biostatistics, Karolinska Institutet. He completed his PhD in psychiatric epidemiology at Karolinska Institutet in 2013, and did his postdoc at University of Oxford and University of Chicago afterwards. Zheng’s research has focused on understanding the risks and benefits of prescribed psychotropic medications, particularly ADHD medications, using large population-based data. He has strong skills in advanced pharmacoepidemiology designs and statistical analyses. He has over 50 publications, including a number of papers published in leading medical and psychiatric journals.

Fredrik Hieronymus

Fredrik Hieronymus undertook his PhD studies at the University of Gothenburg. His PhD project focussed on evaluating the specific effects of selective serotonin reuptake inhibitor (SSRI) treatment when used for major depression. Through the use of individual patient-level data from a comprehensive collection of randomized controlled trials, it was found that the symptoms included in the Hamilton Depression Rating Scale (HDRS) demonstrate markedly different response trajectories over time, that much information is lost when converting item-level information into the HDRS sum-score, and that the HDRS sum-score underestimates antidepressant efficacy partly due to the inclusion of HDRS items that may reflect common SSRI side-effects. Fredrik Hieronymus is now a post-doctoral researcher at Aarhus University where he continues to study the efficacy and safety of pharmacological treatments for depression, bipolar disorder and psychosis.
Bin Zhang

Dr. Bin Zhang works as a Junior PI in the Affiliated Brain Hospital of Guangzhou Medical University. He studied Medicine in Tianjin Medical University (China), completed the Integrative Neuroscience Program and obtained his PhD degree at Otto von Guericke University of Magdeburg (Germany). His research focuses on emotion and cognition interaction and neuropsychopharmacology using functional and structural MRI. He has got three research grants of Chinese government to do psychiatric research, especially neuropsychopharmacology. He has published 18 peer review articles.

Friday 4 October 2019
10:00 – 10:10 | Room: Olympia Hall

Rafaelsen Young Investigators Awards Presentation

Please view the posters presented by our Rafaelsen Awardees which will be displayed during the Meeting:

<table>
<thead>
<tr>
<th>Poster number</th>
<th>Presentation day</th>
<th>Name</th>
<th>Poster Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>PS02.10</td>
<td>Friday 4 October</td>
<td>Zheng Chang Sweden</td>
<td>ADHD medication and behavioral and neuropsychiatric outcomes: real-world evidence from pharmacoepidemiology studies</td>
</tr>
<tr>
<td>PS01.30</td>
<td>Thursday 3 October</td>
<td>Fredrik Hieronymus Denmark</td>
<td>The Hamilton Depression Rating Scale Measures Side Effects and Therefore Underestimates the Antidepressant Effect of SSRIs and SNRIs</td>
</tr>
<tr>
<td>PS01.25</td>
<td>Thursday 3 October</td>
<td>Bin Zhang China</td>
<td>Ketamine eliminates suicidal ideation in MDD patients associated with kynurenine metabolism mediating brain activity of middle temporal gyrus</td>
</tr>
</tbody>
</table>
Keynote Speakers

Thursday 3 October 2019
09:00 – 10:00 | Room: Olympia Hall

Rapid acting antidepressants: opportunities and mechanisms

John H. Krystal,
Yale School of Medicine, USA

Dr. Krystal is the Robert L. McNeil, Jr., Professor of Translational Research; Professor of Psychiatry, Neuroscience, and Psychology; and Chair of the Department of Psychiatry at Yale University. He is also Chief of Psychiatry and Behavioral Health at Yale-New Haven Hospital. He is a graduate of the University of Chicago, Yale University School of Medicine, and the Yale Psychiatry Residency Training Program. He has published extensively on the neurobiology and treatment of schizophrenia, alcoholism, PTSD, and depression. Notably, he led the discovery of the rapid antidepressant effects of ketamine in humans. He is the Director of the NIAAA Center for the Translational Neuroscience of Alcoholism and the Clinical Neuroscience Division of the VA National Center for PTSD. Dr. Krystal is a member of the U.S. National Academy of Medicine. Currently, he is a member of the NIMH National Mental Health Advisory Council; co-director of the Neuroscience Forum of the U.S. National Academies of Sciences, Engineering, and Medicine; and editor of Biological Psychiatry (IF=11.982). He is past president of the American College of Neuropsychopharmacology (ACNP) and International College of Neuropsychopharmacology (CINP).

Abstract: Until the discovery of the antidepressant effects of ketamine, all of the medications used to treat depression were variations of treatments discovered in the late 1950s. Although they help many people, these medications have many limitations that are well known to people who have struggled with depression. To get new types of antidepressants, we had to think differently about the brain and the biology of depression. This presentation will highlight the change in perspective that led us to discover the rapid and robust antidepressant effects of ketamine in depressed patients. I will then briefly describe what the field of depression research is learning about ketamine and esketamine (Spravato) that led to the FDA approval of Spravato in March, 2019. Lastly, I will show how the crosstalk between basic and clinical neuroscience has led to the hypothesis that ketamine and Spravato may work by helping the brain regrow synaptic connections between nerve cells that were lost due to the impact of stress and depression on the brain. These new connections appear to enable circuits regulating mood to function more effectively. Ultimately, this is a story about hope. It highlights that there are opportunities for fundamental discovery that cannot be anticipated and that can profoundly change the lives of people with depression and other illnesses.

Thursday 3 October 2019
14:30 – 15:30 | Room: Olympia Hall

The future of manualized versus personalized psychiatry

Tarek Okasha,
Ain Shams University, Cairo, Egypt
Abstract: The goal of achieving personalized medicine in psychiatry is praise worthy, because its attainment should be associated with a marked reduction in morbidity and mortality. Studies that are laying the foundation towards personalizing medicine in major depressive disorder, bipolar disorder, and schizophrenia are starting to evolve even if in its infancy. The holistic, systems-oriented approach, which may be well-positioned to fill the gap between the need for rigorous and rational psychiatry and the need for personalized medicine may not be enough. Personalized medicine has five main pillars, personalized, participatory, predictive, preventive, psycho-cognitive, they could establish links between psychiatric diseases, which are disorders with a final common symptomatology with vastly heterogeneous biological, environmental and sociological underpinnings.

Psychiatry is emerging as something of a unique medical field in which a novel approach is demanded and needed for properly treating patients through a more targeted and tailored diagnosis and therapy, taking into account the complex interactions among genes and their products, environment, and culture. This presentation will cover emerging applications that are likely to advance personalized medicine in psychiatry, as well as comparing between manualized and personalized psychiatry.
Antidepressants work: of panic disorder, being involved in the first disorders. He and his co-workers were early monoamines for the treatment of psychiatric disorders. Eriksson’s preclinical and clinical studies have previously been chairman of the Swedish Society for Biological Psychiatry and the Swedish Association (WPA) Section of Pharmacopsychiatry (WFSBP) and has been appointed as President of the WFSBP in 2013. He has been elected to the Executive Committee of the International College of Neuropsychopharmacology (CINP) for the period of 2012 to 2018 and is now President of this society. Moreover, Dr. Kasper is Chair of the World Psychiatric Association (WPA) Section of Pharmacopsychiatry. He is Founding President of the Austrian Society of Neuropsychopharmacology and Biological Psychiatry (ÖGPB) and of the Austrian Society of Drug Safety in Psychiatry (ÖAMSP). Furthermore, he is a Honorary Member of the Czech Society of Neuropsychopharmacology, the Romanian Society of Neuropsychopharmacology, the Hungarian Psychiatric Association and a Fellow of the Royal College of Psychiatrists, UK, as well as of the Scandinavian College of Neuro-Psychopharmacology (SCNP) and of the Ukrainian Association of Psychiatry. He is a member of the European Academy of Sciences and Arts (EASA). Furthermore, he has been appointed as Honorary/Visiting Professor at the following universities: University of Hong Kong, China, in 2004; Universidad Andrés Bello, Santiago de Chile, Chile, 2014; Aino University in Osaka, Japan, 2015; Kolkata Institute of Psychiatry, Department of Health & Family Welfare, India in 2016; University of Hiroshima, Japan, in 2017 and Belgrade University School of Medicine, Serbia, in 2017. Dr. Kasper serves on editorial boards of numerous learned journals, including The Lancet Psychiatry, Journal of Clinical Psychiatry, CNS Spectrums, Journal of Affective Disorders, Pharmacopsychiatry, European Archives of Psychiatry and Neuroscience. He is Chief-Editor of the World Journal of Biological Psychiatry and the International Journal of Psychiatry in Clinical Practice, and Field Editor of the International Journal of Neuropsychopharmacology as well as Section Editor of the Annals of General Psychiatry.

As a result of his research expertise he is the recipient of numerous national and international scientific and public awards and prizes and has been acknowledged with the Grand Decoration of Honor in Silver for Services to the Republic of Austria, the Austrian Cross of Honor for Science and Art, First Class and the City of Vienna Award for Medical Science.

Abstract: Despite consistent advances in pharmacotherapy of mood disorders in the last decade, high rates of Treatment Resistant Depression (TRD) are still a challenging aspect of overall management. The group for the study of resistant depression (GSRD), a collaborative project between eight European centres in Belgium, France, Greece, Italy, Israel and Austria studied TRD patients thoroughly and described a set of eleven variables associated with treatment.
resistance, among them co-morbid anxiety disorders and melancholic features. The GSRD European multicentre project includes more than 2700 patients including clinical, pharmacological as well as molecular-biological variables. One potential way of improving the treatment of TRD is the use of predictive biomarkers, including genetic parameters in combination with clinical variables. The advent of new treatments may also help by focusing on neurotransmitters other than serotonin, e.g. the glutamatergic system with ketamine demonstrating efficacy data in TRD as well as in depressed patients with suicidality. Furthermore, pharmacological strategies like the use of combination therapy with lithium, atypical antipsychotics and the development of other pharmacological agents -like brexanolone- can improve outcomes, and techniques such as deep brain stimulation and vagus nerve stimulation have shown promising results. Literature: Bartova L, Dold M, Kautzky A, Fabbri C, Spies M, Serretti A, Souery D, Mendlewicz J, Zohar J, Montgomery S, Schosser A, Kasper S (2019) Results of the European Group for the Study of Resistant Depression (GSRD) — Basis for further research and clinical practice. World Journal of Biological Psychiatry, epub ahead of print 25 Jul 2019, DOI: 10.1080/15622975.2019.1635270
Keyword: Depression, treatment-resistant, Ketamine, Brexanolone
Keynote Speakers

Friday 4 October 2019
13:30 – 14:30 | Room: Olympia Hall

Antidepressants work: The evidence

Elias Eriksson,
University of Gothenburg, Sweden

Elias Eriksson began his studies in medicine at the University of Gothenburg in 1975. Having had his scientific training at the department of pharmacology, led by monoamine pioneer and Nobel prize winner Arvid Carlsson, Eriksson became Med Dr. in 1985, associate professor in 1988 and researcher at the Swedish MRC in 2000. From 2001 he has been professor of pharmacology at the University of Gothenburg. Eriksson is the author of approximately 300 papers mainly in the fields of preclinical and clinical psychopharmacology and has been invited speaker at >100 scientific international meetings. He has been main supervisor for 18 PhD students. He has previously been chairman of the Swedish Society for Biological Psychiatry and the Swedish Serotonin Society and a board member of the Scandinavian College of Neuropsychopharmacology and the Swedish Schizophrenia Foundation. He is a member of the Scientific Council for Medicine and Health in Sweden and an honorary member of the Swedish Society for Biological Psychiatry and the Swedish Serotonin Society.

Eriksson’s preclinical and clinical studies have mainly been related to the importance of monoamines for the treatment of psychiatric disorders. He and his co-workers were early advocates of a role for serotonin in the treatment of panic disorder, being involved in the first approval of an antidepressant (clomipramine) for this disorder, and the first to show serotonin reuptake inhibitors to exert a prompt and dramatic symptom reduction in premenstrual dysphoric disorder. They have conducted numerous preclinical and clinical studies aiming to shed light on why inhibition of the serotonin transporter causes symptom reduction in so many disparate conditions, some effects occurring early and some requiring weeks of treatment to be maximal.

Eriksson and co-workers have also taken an interest in the ongoing debate regarding the alleged ineffectiveness of antidepressants, publishing a number of patient-level meta-analyses suggesting the questioning of these drugs to be largely unfounded. Eriksson and co-workers have also studied dopaminergic receptors, and were, e.g., the first to establish the pharmacological similarities between D2 autoreceptors in brain and prolactin-regulating D2 receptors in the pituitary. Studying the influence of haloperidol on D2-receptor-mediated regulation of prolactin release in vitro, they were also the first to provide functional evidence for the fact that a G protein-coupled receptor may be the subject of inverse agonism.

Abstract: While some debaters have gained extensive attention in scientific and lay media for the claim that antidepressants are devoid of a specific antidepressant action, official bodies issuing treatment guidelines usually acknowledge that they are effective, but have downplayed their usefulness, especially in non-severe depression. In this presentation, results from recent patient-level, item-specific post hoc analyses of company-sponsored placebo-controlled trials addressing a number of aspects related to the efficacy of common antidepressants will be presented. It is concluded that the three SSRIs under investigation (citalopram, paroxetine, sertraline) i) display a consistent superiority over placebo across trials with respect to the reduction in depressed mood, ii) that this effect is not (as has been claimed) independent of dose, iii) that it is apparent (though modest) already after one week of treatment, iv) that its effect size in patients given an optimal dose is well on par with
that of most drugs used in somatic medicine, vi) that it is not caused by side effects breaking the blind, and vii) that it is of the same magnitude in “non-severe” as in “severe” depression. It will also be reported vii) that the net effect of these drugs on suicidality is beneficial already from week 1, but that vii) subjects on SSRIs more often than those on placebo display an early increase in somatic but not psychic anxiety. Most of these results could be replicated in similar analyses of an SNRI, duloxetine. No major differences between the SSRIs and duloxetine in symptom profile was observed.

**Neuroactive steroids as rapid-acting antidepressants: The story of brexanolone and SAGE-217**

**Stephen Kanes,**
SAGE Therapeutics Inc., USA

Dr. Steve Kanes is responsible for Sage's clinical-stage programs and is the company’s primary liaison with the investigator community. His experience as a practicing psychiatrist helped him advance through increasing positions of responsibility at AstraZeneca Pharmaceuticals, culminating in his role as the Executive Director/Therapeutic Area Clinical Director for the inflammation, neuroscience, and respiratory GMED division at the company. He is an adjunct assistant professor of psychiatry at the University of Pennsylvania School of Medicine and has authored or co-authored more than 30 peer-reviewed publications. He serves as an ad hoc reviewer for the journals Neuropsychopharmacology, American Journal of Medical Genetics, and Biological Psychiatry.

Steve received his B.A. from the University of Pennsylvania and both his Ph.D. and M.D. from State University of New York, Stony Brook. He completed his psychiatry residency at Yale-New Haven Medical Center and postdoctoral fellowship at the University of Pennsylvania.
Saturday 5 October 2019
09:00 – 10:00 | Room: Olympia Hall

ALEC COPPEN KEYNOTE LECTURE

Interactions between neurotransmitters: the key to remission in depression

Pierre Blier,
University of Ottawa, Canada

Dr. Pierre Blier is a Full Professor for the Departments of Psychiatry and Cellular & Molecular Medicine in the Faculty of Medicine at the University of Ottawa in Ottawa, Ontario, Canada, and the Director of the Mood Disorders Research Unit at The Royal’s Institute of Mental Health Research.

Dr. Blier is on the editorial boards of several journals and is the co-editor in chief for the Journal of Psychopharmacology and field editor for translational medicine for the official journal of International College of Neuropsychopharmacology (CINP). In addition to his extensive list of publications and lectures presented worldwide, Dr. Blier has contributed to several treatment guidelines for psychiatric disorders. Dr. Blier has a basic research laboratory investigating how psychotropic medications work in the brain, he carries out investigator-initiated clinical studies, and treats patients with mood and anxiety disorders on a daily basis.

Dr. Blier received several awards for outstanding contributions to psychopharmacology including the Canada Research Chair in Psychopharmacology from the Government of Canada and is now a Fellow of the Royal Society of Canada (Life Sciences). He also serves on several committees, including the presidency elect of the CINP.

Saturday 5 October 2019
12:00 – 13:00 | Room: Olympia Hall

New pharmacological treatments for resistant depression

Maurizio Fava,
Massachusetts General Hospital, USA

Dr. Maurizio Fava is director, Division of Clinical Research of the Massachusetts General Hospital (MGH) Research Institute, executive chair of the Department of Psychiatry and executive director of the Clinical Trials Network and Institute, (MGH), and associate dean for clinical and translational research and the Slater Family Professor of Psychiatry at Harvard Medical School. Dr. Fava is a world leader in the field of depression. He has edited eight books and authored or co-authored more than 800 original articles published in medical journals with international circulation, articles which have been cited more than 60,000 times in the literature and with an h index of over 125. Dr. Fava has been successful in obtaining funding as principal or co-principal investigator from both the NIH and other sources for more than $100,000,000. Dr. Fava’s prominence in the field is reflected in his role as the co-principal investigator of STAR*D, the largest research study ever conducted in the area of depression.
PS01 - Guided Poster Session
Thursday 3 October
17:30 - 18:30 | Room: Olympia Foyer

**Chairs:**
- Elias Eriksson, Sweden; Joseph Zohar, Israel; Pierre Blier, Canada

**Topic: Mood**

PS01.01 Comparison of circulating endothelial progenitor cells among patients with mood disorders and normal controls
- **Ya Mei Bai**
  National Yang Ming University, Taipei Veterans General Hospital, Taiwan

PS01.02 Connectome study at resting state in bipolar disorder using magnetoencephalography
- **Yuichi Takei**
  Gunma University, Japan; Tsutsui Mental Hospital, Japan
  1Gunma University, Japan, 2Tsutsui Mental Hospital, Japan, 3Gunma Prefectural Psychiatric Medical Center, Japan, 4Tokyo University, Japan

PS01.03 Patient-reported outcomes in major depressive disorder with suicidal ideation: a real-world data analysis using PatientsLikeMe platform
- **Stephane Borentain**
  Abigail Nash, Rachna Dayal, Allitia Dibernardo
  Janssen Research & Development, LLC, USA

PS01.04 Randomized, double-blind, placebo-controlled study to investigate the effect of vorixetine in AD patients with depression
- **Do Hoon Kim**
  Chunchon Sacred Heart Hospital, South Korea

PS01.05 Vital exhaustion and stroke: gender disparities. WHO epidemiological program
- **MONICA-psychosocial**
  Valery Gafarov, Elena Gromova, Dmitrij Panov, Igor Gagulin, Almira Gafarova, Eldar Krymov
  Institute of Internal and Preventive Medicine - branch of Institute of Cytology and Genetics, Russian Federation

PS01.06 Improving Emotion Regulation and Mood and Reducing Suicide Risk in Bipolar Disorder by Regularizing Daily Rhythms
- **Hilary Blumberg**
  1Yale School of Medicine, USA, 2University of Pittsburgh Medical Center, USA

PS01.07 Does LSD have antidepressive potentials? Lessons to be learned from early psychedelic therapy in Denmark
- **Jens Knud Larsen**
  Birgitte Bjerg Bendsen
  1Aarhus University Hospital, Denmark, 2University Hospital of Copenhagen, Denmark

PS01.08 A Phase 3, Double-Blind, Placebo-Controlled Trial of the Neuroactive Steroid SAGE-217 in Postpartum Depression: Assessment of Depressive Symptoms Across Multiple Measures
- **Stephen Kaner**
  Robert Lasser, Handan Gunduz-Bruce, Christopher Silber, Abdul Sankoh, Sigui Li, Jeff Jonas, James Doherty, Kristina Deligianidis
  1SAGE Therapeutics, Inc., USA, 2Zucker Hillside Hospital, USA

PS01.09 Efficacy and Safety of the Neuroactive Steroid Brexanolone in Women with Postpartum Depression: Integrated Analyses of Clinical Data
- **Sonmi Park**
  Helen Colquhoun, Samantha Meltzer-Brody, Robert Riesenberg, C. Neill Epperson, Kristina Deligiannidis, David Rubinow, Haihong Li, Stephen Kaner
  1Sage Therapeutics, Switzerland, 2Sage Therapeutics, USA, 3UNC School of Medicine, USA, 4Atlanta Center for Medical Research, USA, 5University of Colorado School of Medicine, USA, 6Zucker Hillside Hospital, USA, 7University of North Carolina at Chapel Hill, USA, 8Sage Therapeutics, USA
PS01.10 Aberrant cortical connectivity revealed by the heartbeat evoked magnetic fields (HEFs) in patients with mood disorders

Yutaka Kato1,2, Yuichi Takei1, Satoshi Umeda1, Masaru Mimura1, Masato Fukuda2
1Tsutsuji Mental Hospital, Japan, 2Gunma University, Japan

PS01.11 SAGE-217 a First in Class Neuroactive Steroid and GABAA Receptor Positive Allosteric Modulator being developed for Major Depressive Disorder: A Multicenter, Randomized, Double-blind, Pivotal Placebo-controlled Trial

Stephen Kanes1, Christopher Silber1, Anthony Rothschild1, Robert Riesenber1, Abdul Sankoh2, Haiphong Li2, Ella Li2, Charles Zoromski2, David Rubinow2, Steven Paul2, Jeff Jonas3, James Doherty3, Handan Gunduz-Bruce2
1SAGE Therapeutics, Inc, USA, 2SAGE Therapeutics, USA, 3University of Massachusetts Medical School, USA, 4Atlanta Center for Medical Research, USA, 5Washington University School of Medicine, USA, 6University of North Carolina at Chapel Hill, USA, 7Karuna Pharmaceuticals, Inc., USA

PS01.12 Changes in the connectome according to body mass index in healthy females: a magnetoencephalography study

Masashi Suda1, Yuichi Takei1,2, Yutaka Kato4, Minami Tagawa1, Noriko Sakurai1, Masato Fukuda1
1Gunma University, Japan, 2Gunma University, Japan, 3Gunma University Graduate School of Medicine, Japan, 4Tsutsuji Mental Hospital, Japan

PS01.13 Suicide attempt is highly associated with extreme cold environments and molecular pathways of cancer

Christina Kyriakou, Konstantinos Voskarides, Andreas Chatzitzitofis
University of Cyprus, Medical School, Cyprus

PS01.14 Unique Pharmacology and Clinical Evidence Supporting the Antidepressant Therapeutic Potential of Lumateperone

Torgny H. Svensson1, Robert Davis2, Sophie Dutheil2, Joseph Hendrick2, Lei Zhang3, Lawrence Wennegle4, Andrew Satlin5, Monica Marcus6, Joep Titulaer1,7, Sharon Mates6, Kim Vanover1, Gretchen Snyder7
1Karolinska Institutet, Sweden, 2Intra-Cellular Therapies, Inc., USA, 3Uppsala University, Sweden

PS01.15 Association between human in vivo metabotropic glutamate receptor-5 availability and white matter microstructural integrity: a multimodal imaging study

Jong-Hoon Kim1, Song-E Kim1, Yo-Han Joo1, Young-Don Son1, Sang-Yoon Lee1, Hang-Keun Kim1
1Department of Psychiatry, Gachon University College of Medicine, South Korea, 2Neuroscience Research Institute, Gachon University, South Korea, 3Department of Biomedical Engineering, College of Health Science, South Korea, 4Department of Neuroscience, Gachon University College of Medicine, South Korea

PS01.16 Effects of Nrx4 on stress-induced amygdala-centered resting state functional connectivity

Meng Li1, Melanni Nanni1, Yan Fan2, Vanessa Kasties3, Tara Chand1, Luisa Herrmann1, Tibor Tar1, Myron Schultz2, Martin Walter1
1Clinical Affective Neuroimaging Laboratory, Germany, 2Leibniz Research Centre for Working Environment and Human Factors, Germany, 3Biologische Heilmittel Heel GmbH, Germany, 4Biologische Heilmittel Heel GmbH, Germany

PS01.17 Nrx4 influences association of EEG with amygdala activation and connectivity after stress

Nooshin Javaheripour1,2, Marina Krylova1, Yan Fan1, Sara Alizadeh1,3, Hamidreza Jamalabadi1,3, Luisa Herrmann1,2, Anne Kühnel1, Lena Danyeli1,4, Tibor Tar5, Myron Schultz2, Martin Walter1,2,4,5
1Clinical Affective Neuroimaging Laboratory, Germany, 2Universitäts Klinikum Tübingen, Germany, 3University Tübingen, Germany, 4Leibniz Institute for Neurobiology, Germany, 5Biologische Heilmittel Heel GmbH, Germany
PS01.18 Bright light therapy in seasonal affective disorder – a meta-analysis of available evidence
Edda Winkler-Pjrek1, Michaela-Elena Friedrich1, Luca Cambioli1, Markus Dold1, Fiona Jäger2, Arkadiusz Komorowski1, Rupert Lanzenberger1, Siegfried Kasper1, Dietmar Winkler1
1Medical University of Vienna, Austria, 2University Medical Center Freiburg, Germany

PS01.19 Depression in patients with psychosis - impact on treatment motivation and satisfaction
Dietmar Winkler, Sabine Lürzer, Leo Silberbauer, Siegfried Kasper, Edda Winkler-Pjrek
Medical University of Vienna, Austria

PS01.20 Interaction of PSD95 with GluN2B subunit in different conditions of cocaine forced abstinence in rat brain structures
Irena Smaga-Masłanka1,2, Karolina Wydra2, Lucia Caffino3, Fabio Fumagalli3, Marek Sanak1, Malgorzata Filip
1Jagiellonian University Medical College, Poland, 2Polish Academy of Sciences, Poland, 3University of Milano, Italy

PS01.21 Vitamin D3 modulates depression-like behavior and expression of NF-kB and 17β-estradiol receptor in adult ovariectomized rat exposed to unpredictable chronic mild stress
Aleksandra Koshkina1, Tatyana Dudnichenko2, Denis Baranenko3, Julia Fedotova1,2
1ITMO University, Russian Federation, 2North-Western State Medical University named after I.I. Mechnikov, Russian Federation, 3I.P. Pavlov Institute of Physiology RASci, Russian Federation

PS01.22 Co-administration of Vitamin D3 and escitalopram attenuates depression-like behavior and modulates BDNF, NT-3 and NT-4 expressions in the hippocampus of the adult ovariectomized rats subjected to chronic unpredictable stress
Julia Fedotova1,2,3, Denis Baranenko1,4, Alexandra Koshkina1, Tatyana Dudnichenko1
1ITMO University, Russian Federation, 2I.P. Pavlov Institute of Physiology RASci, Russian Federation, 3North-Western State Medical University named after I.I. Mechnikov, Russian Federation, 4Faculty of Food and Bioengineering, ITMO University, Russian Federation

PS01.23 Hostility as a risk factor for suicide attempts in patients with major depressive disorder
Kyoung-Uk Lee
Uijeongbu St. Mary’s Hospital, The Catholic University of Korea, South Korea

PS01.24 The Monoamine Oxidase Inhibitor Isocarboxazid: A clinical update
Jens Knud Larsen1, Kerstin Fredricson Overø2, Lene Krogh-Nielsen3, Eva Rask-Pedersen1, K. Broksen3
1Aarhus University Hospital, Denmark, 2Medilink A/S, Kgs., Denmark, 3Odense University Hospital, Denmark

PS01.25 Ketamine eliminates suicidal ideation in MDD patients associated with kynurenine metabolism mediating brain activity of middle temporal gyrus
Bin Zhang1, Meng Li2, Yanling Zhou1, Yanni Zhan1, Yuning Ning1
1Affiliated Brain Hospital of Guangzhou Medical University, China, 2Clinical Affective Neuroimaging Laboratory, Germany

PS01.26 Plasma Serotonin Levels Correlated with Depressive Symptoms in Major Depressive Disorder
Jessica Mills1,2, Chao Deng1,2, Susan Thomas1,2, Theresa Larkin1,2
1Illawarra Health and Medical Research Institute, Australia, 2School of Medicine, University of Wollongong, Australia

PS01.27 Employment Status and Pharmacotherapy of Japanese Outpatients With Mood Disorders
Yukinori Kamata, Osamu Takashio, Marie Ota, Ayaka Sato, Yousuke Sawanobori, Hiromitsu Uno, Hideaki Kawai, Mari Yamada, Tomohiro Yoshida, Tomoyuki Tachibana, Haruka Yanagihara, Shutarou Sugita, Akira Iwanami
School of Medicine, Showa University, Japan
PS01.28 The role of oxytocin in suicidal behavior of male and female affective disorder patients  
Marleen Margret Mignon Mitschek¹, Klemens Kienesberger¹, Nestor Kapusta¹, Birgit Ludwig¹,  
Alexandra Bernegger¹, Laura Carlberg¹, Patrick Swoboda¹, Romina Koller¹, Martin Aigner²,  
Helmuth Haslacher¹, Siegfried Kasper¹,  
Alexandra Schosser¹,²,³,⁴  
¹Medical University of Vienna, Austria, ²Karl Landsteiner University for Healthsciences, Austria,  
³Zentren für seelische Gesundheit BBRZ-Med, Austria, ⁴Arbeitsgemeinschaft für Verhaltensmodifikation (AVM), Austria

PS01.29 Association of Heart Rate Variability with Psychiatric Disturbances in Patients with Multiple Sclerosis and Neuromyelitis Optica  
Joon Sung Shim¹, Young Nam Kwon², Yoobin Choi¹, Jae Yeon Lee³, Yoonji Irene Lee¹, Ju Hyun Hwang¹, Sung-Min Kim², Soo-Hee Choi¹  
¹Department of Psychiatry, Seoul National University Hospital, South Korea, ²Department of Neurology, Seoul National University Hospital, South Korea

PS01.30 The Hamilton Depression Rating Scale Measures Side Effects and Therefore Underestimates the Antidepressant Effect of SSRIs and SNRIs  
Fredrik Hieronymus¹,², Alexander Lisinski³, Elias Eriksson³, Sören Dinesen Østergaard¹,⁴  
¹Department of Clinical Medicine, Aarhus university, Denmark, ²Institute of Neuroscience and Physiology, University of Gothenburg, Sweden, ³University of Gothenburg, Sweden, ⁴Department of Affective Disorders, Aarhus University, Denmark

PS01.31 LY341495 induces antidepressant-like effects in the chronic unpredictable stress model of depression in C57BL/6J mice and enhances the antidepressant action of ketamine in this model  
Agnieszka Palucha-Poniewiera, Karolina Podkowa, Anna Rafalo-Ulińska  
Maj Institute of Pharmacology Polish Academy of Sciences, Poland

PS01.32 Zinc Deficiency: An essential Variable for the Induction of Resistance to Antidepressants  
Anna Rafalo-Ulińska¹, Bartłomiej Pochwat¹, Dominika Siodlak¹, Paulina Misztak¹, Bożena Muszyńska², Agata Kryczk², Włodzimierz Opoka³, Gabriel Nowak¹, Bernadeta Szewczyk¹  
¹Maj Institute of Pharmacology Polish Academy of Sciences, Poland, ²Department of Pharmaceutical Botany, Jagiellonian University Medical College, Poland, ³Department of Inorganic Chemistry, Jagiellonian University Medical College, Poland

PS01.33 Increased adrenocorticotropic hormone (ACTH) levels predict severity of depression after six months of follow-up in outpatients with major depressive disorder  
Ji Hyun Yoo¹, Kwan Woo Choi, Eun Jin Na, Maurizio Fava, David Mischoulon, Hana Cho, Hong Jin Jeon  
Samsung Medical Center, South Korea

PS01.34 Ratio of Plasma BDNF to Leptin Levels are Associated with Treatment Response in Major Depressive Disorder but Not in Panic Disorder: A 12-Week Follow-up Study  
Dong Yeun Yook¹, Ji Hyun An¹, Eun Hye Jang², Ah Young Kim², Maurizio Fava³, David Mischoulon⁴, George Papakostas⁵, Eun Jin Na¹, Jihoon Jang¹, Han Young Yu², Jin Pyo Hong¹, Hong Jin Jeon¹  
¹Depression Center, Samsung Medical Center, South Korea, ²Electronics and Telecommunications Research Institute (ETRI), South Korea, ³Massachusetts General Hospital, Harvard Medical School, USA, ⁴Samsung Medical Center, Sungkyunkwan University School of Medicine, South Korea

PS01.35 Pre-treatment peripheral biomarkers associated with treatment response in panic symptoms in patients with major depressive disorder and panic disorder: a 12-week follow-up study  
Hong Jin Jeon¹, Eun Hye Jang, Ah Young Kim, Maurizio Fava, David Mischoulon, George Papakostas, Hyewon Kim, Eun Jin Na, Han Young Yu  
Samsung Medical Center, Sungkyunkwan University School of Medicine, South Korea
PS01.36 Efficacy of ziprasidone monotherapy in patients with anxious depression: a 12-week, randomized, double-blind, placebo-controlled, sequential-parallel comparison trial

Seonah Lee¹, Yoon Jung Jang², Maurizio Fava³, Hong Jin Jeon⁴, George Papakostas⁵, David Mischoulon⁶, Jung Yoon Heo⁷, Baer Lee⁸, Clain Alisabet⁹, Doorley James¹⁰, Pisoni Angela¹⁰, LPapakostas George¹
¹Samsung Medical Center, Sungkyunkwan University School of Medicine, South Korea, ²Sungkyunkwan University School of Medicine, South Korea, ³Samsung Medical Center, South Korea

PS01.37 Predictors of alcohol use disorder in acutely depressed patients across unipolar and bipolar spectrum

Minseok Hong¹, Tae Hyon Ha², Woojae Myung³, Soo Yeon Lee²
¹Department of Psychiatry, Seoul National University Hospital, South Korea, ²Department of Neuropsychiatry, Seoul National University Bundang Hospital, South Korea

PS01.38 Biomarkers of depression in skin – a pre-clinical approach

Erik Kaadt¹, Birgitte Mummi¹, Sanne Andersen³, Christian Damgaard¹, Betina Elfving²
¹Aarhus University - Department of Clinical Medicine - Translational Neuropsychiatry Unit, Denmark, ²Translational Neuropsychiatry Unit, Aarhus University, Denmark, ³Aarhus University - Department of Clinical Medicine - Translational Neuropsychiatry Unit, Denmark, ⁴Institute for Molecular Biology and Genetics, Aarhus University, Denmark

PS01.39 Double-blind, placebo-controlled Phase 1 Single Ascending Dose Study of SAGE-718

Harald Murck¹, James Paskavitz², Ethan Hoffmann¹, Sigui Li², Christopher Silber², Michael Quirk¹, Mustafa Varoglu¹, Irena Webster¹, Abdul Sankoh², James Doherty³, Stephen Kanes²
¹Sage Therapeutics/Murck-Neuroscience LLC, USA, ²SAGE Therapeutics, USA

PS01.40 Psychophysiological Characteristics of Insomnia Patients Measured by Biofeedback System

Sung Young Huh¹, Kyung Ha Noh²
¹Pusan National University Yangsan Hospital, South Korea, ²Good-Gang An Hospital, South Korea

PS01.41 Treatment of insomnia in the elderly: a systematic review and meta-analysis

Myrto Samara, Maximilian Huhn, Stefan Leucht
Dept. of Psychiatry and Psychotherapy, TU-München, Germany

PS01.42 Psychosocial Intervention for Discontinuing Benzodiazepine Hypnotics in Patients with Chronic Insomnia: A Systematic Review and Meta-analysis

Yoshikazu Takaesu¹, Tomohiro Utsumi², Isa Okajima³, Akiyoshi Shimura³, Nozomu Kotorii³, Kenichi Kuriyama⁴, Hidehisa Yamashita⁴, Masahiro Suzuki⁵, Norio Watanabe⁵, Kazuo Mishima⁶
¹Kyorin University, Japan, ²Jikei University, Japan, ³Tokyo Kasei University, Japan, ⁴Tokyo Medical University, Japan, ⁵Karume University, Japan, ⁶National Center of Neurology and Psychiatry, Japan, ⁷Hiroshima University, Japan, ⁸Nihon University, Japan, ⁹Kyoto University, Japan, ¹⁰Akita University, Japan

PS01.43 Polysomnographic Features of Opiate Use Disorder

Ahmed Elsheshai¹, Jaidaa Mekky², Ossama Elkholy³, Ahmed Rady³, Tarek Molokhia³
¹Maamoura Psychiatric Hospital, Egypt, ²Alexandria, Egypt

PS01.44 Perampanel in patients with resistant insomnia without epilepsy

Eugenio Suarez Gisbert¹, Maria Jose Abenza²
¹Psychiatric Department, University Hospital Infanta Sofia San Sebastian De Los Reyes, Spain, ²Neurology Department, University Hospital Infanta Sofia San Sebastian De Los Reyes, Spain

PS01.45 Depression Anxiety outcome: Insomnia, Headache and to-date treatments

Habib A. Rabbani
Ste Anne University Hospital, Paris, France
PS01.46 The neural substrates of risky rewards and losses across healthy volunteers and patient group using PET imaging
Nikolina Skandali1,2, Juho Jouts3,4,5, Jonas Majuri1,3,6,7, Kwangyeol Baek1, Evelina Arponen7, Sarita Forsback7, Valterri Kaasinen1,7, Valerie Voon1,2,8
1University of Cambridge, UK, 2Cambridgeshire and Peterborough NHS Foundation Trust, UK, 3Department of Neurology, University of Turku, Finland, 4Athinous A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, USA, 5Berenson-Allen Center for Noninvasive Brain Stimulation, Beth Israel Deaconess Medical Center and Harvard Medical School, USA, 6Division of Clinical Neurosciences, Turku University Hospital, Finland, 7Turku PET Centre, University of Turku, Finland, 8NIHR Biomedical Research Centre, University of Cambridge, UK

PS01.47 Disrupted local and distal functional connectivity development in the supramarginal gyrus in 3 to 10 year old children with autism spectrum disorder: A cross-sectional study
Narae Yoon1, Yebin D Ahn1, Soomin Jang1, Jaewon Song1, Hyungso Park1, Gyahye Noh1, Jung Lee1, Hyejin Kang2, Bung-Nyun Kim1
1Department of Neuropsychiatry, Seoul National University Hospital, South Korea, 2Department of Nuclear Medicine, Seoul National University Hospital, South Korea

PS01.48 Vafidemstat: An epigenetic drug with emerging therapeutic potential, composite data from three psychiatric disorders from the REIMAGINE trial
Josep Antoni Ramos-Quiroga1, Roger Bullock2, Marc Ferrer1, Sonia Gutierrez2, Vanesa Richarte1, Laura Gisbert1, Benjamin Lara1, Marta Valverde1, Michael Ropacki2, Carlos Buesa1
1Hospital Universitario Valle de Hebrón, Valle de Hebrón Research Institute (VHRI), Spain, 2Oryzon Genomics SA, Spain, 3Oryzon Genomics SA, Spain, 4Universidad Autónoma de Barcelona, CIBERSAM, Spain

PS01.49 Preliminary stress exposures are modify the side effects of glucocorticoids drug Triamcinolone Acetonide in respect to behavior activity, thymus and adrenal glands involution in Wistar rats
Vadim Tseylikman1, Olga Tseylikman1, Maxim Lapshin1, Mariya Komelkova1, Alexey Sarapultsev2
1South Ural State University, Russian Federation, 2Institute Immunology and Physiology, Russian Federation

PS01.50 Ghrelin in brain reward circuits
Eliot Gardner, Zhi-Bing You, Tristram Buck, Chloe Jordan, Bree Humbug, Ewa Galaj, Guo-Ha Bi, Zheng-Xiong Xi, Lorenzo Leggio, Allamar Moore
U.S. National Institute on Drug Abuse (NIH), USA

PS01.51 Impulsivity in Gambling Disorder and Problem Gambling: A Meta-analysis
Roxanne Hook1, Konstantinos Ioannidis1, Katie Wickham1, Jon Grant1, Samuel Chamberlain1
1University of Cambridge, UK, 2University of Chicago, USA

PS01.52 A Literature Overview of Virtual Reality (VR) in Treatment of Psychiatric Disorders: Recent Advances and Limitations
Mi Jin Park1, Dong Jun Kim2, Eun Jin Na3, Un Joo Lee4, Hong Jin Jeon2
1Samsung Medical Center, South Korea, 2Samsung Advanced Institute for Health Sciences & Technology, South Korea, 3Depression Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, South Korea, 4Hallym University, South Korea

PS01.53 Choosing wisely of Apolipoprotein E genetic testing in Alzheimer’s disease
Hyunju Yang, Joonhyuk Park
South Korea

PS01.54 Low Diastolic Blood Pressure and Cognitive Decline in Korean Elderly People: The Korean Longitudinal Study on Cognitive Aging and Dementia
Dongyun Lee
Gyeongsang National University Changwon Hospital, South Korea
PS01.55 Early menarche as a risk factor for suicidal ideation in girls: The Korea Youth Risk Behavior Web-Based Survey

You Jung Han1, Dongyoon Lee2
1SAMSUNG Changwon Hospital, South Korea, 2Gyeongsang National University Changwon Hospital, South Korea

PS01.56 Suicide trends in Cyprus between 2004-2017

Christina Kyriakou, Sophia Kyriakou, Andreas Chatzitofis
University of Cyprus, Medical School, Cyprus

PS01.57 Transition Care Program at Hospital Universitario de la Princesa, Madrid

Clara Sanahuja Muñoz
Hospital Universitario la Princesa, Spain

PS01.58 Anxiogenic effect of glucocorticoid drug Triamcinolone Acetonide and alteration in monoamines content in neocortex and hippocampus in rats with low intensity of microsomal oxidation

Vadim Tseylikman, Olga Tseylikman, Mariya Komelkova, Maxim Lapshin
South Ural State University, Russian Federation

PS01.59 PTSD and neurocognitive functioning: Controlling the effects of insomnia and depression

Kyeong-Sook Choi1, Ji-Ae Yun1, Kyoungsook Jeong2, Ys Ahn3
1Eulji University School of Medicine, South Korea, 2Hallym University Sacred Heart Hospital, South Korea, 3Occupational and Environmental Medicine-Yonsei University Wonju College of Medicine-Wonju, South Korea

PS01.60 Strain difference in the side effects of the glucocorticoid drug on the thymus between normal and hypertensive rats: focus on the previous stress exposures

Vadim Tseylikman, Mariya Komelkova, Maxim Lapshin, Olga Tseylikman
South Ural State University, Russian Federation

PS01.61 Correlation Between Specific Component of Mental Health and Psychological Well-Being of Filipino Older People

Perry Espinosa, Mae Joy Espinosa
Woosong College, South Korea

PS01.62 Does down-regulation of 5-HT2A receptors contribute to subchronic SSRI administration reducing context-conditioned fear in rat?

Melker Hagsäter, Robert Pettersson, Jakob Näsland, Elias Eriksson
Institute of Neuroscience and Physiology, Sweden

PS01.63 Protracted Abstinence Syndrome in Recovering Opiate Addicts

Ahmed Elsheshaj1, Jaidaa Mekkya, Ahmed Radya, Ossama Elkholyb, Tarek Molokhiab
1Maamoura Psychiatric Hospital, Egypt, 2Alexandria, Egypt

PS01.64 Spatial co-expression of genes with the enzyme monoamine oxidase A in the human cerebral cortex: a PET and AHBA study

Godber Mathis Godbersen1, Chrysoula Vraka2, Gregor Gryglewski1, René Seiger1, Neydher Berroterán-Infante2, Jakob Unterholzner3, Paul Michenthaler1, Patricia Handschuh1, Andreas Hahn1, Markus Mitterhausera, Wolfgang Wadsak, Siegfried Kasper, Rupert Lanzenberger
1Department of Psychiatry and Psychotherapy, Medical University of Vienna, Austria, 2Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Austria, 3Ludwig Boltzmann Institute Applied Diagnostics, Austria, 4Centre for Biomarker Research in Medicine (CBmed), Austria

PS01.65 Non-psychotic mental disorders in patients with hyperthyroidism and their combined treatment

Olena Pityk, Nikolai Karbovskiy
Ivano-Frankivsk National Medical University, Ukraine
PS01.66 - Behavioral cross-sensitization between cocaine and ethanol is accompanied by parallel changes in the activity of AMPK system

Hyun Soo Ji, Shijie Xu, Ung Gu Kang
Institute of Human Behavioral Medicine, Medical Research Center, Seoul National University, South Korea

PS01.67 Impairments in Cognition in Cannabis Dependent Young Adults

Ayla Selamoglu¹, Christelle Langley², Rebecca Crean², George J Savulich³, Francesca Cormack³, Barbara J. Sahakian⁴, Barbara Mason⁵
¹University of Cambridge, UK, ²The Scripps Institute, USA, ³University of Cambridge, Department of Psychiatry and Behavioural and Clinical Neuroscience Institute, UK, ⁴Cambridge Cognition, UK

PS01.68 Whole-brain imaging and analysis to reveal spatial pattern of Amyloid β plaques

Hiroaki Ono¹, Tomoyuki Mano¹, Chika Shimizu¹, Susaki A. Etsuo¹,², Takashi Saito³,⁴, Takao M. Saito⁴, Hiroki R. Ueda¹,²,⁵
¹University of Tokyo, Japan, ²Laboratory for Synthetic Biology, RIKEN Center for Biosystems Dynamics Research, Japan, ³Laboratory for Proteolytic Neuroscience, RIKEN Center for Brain Science, Japan, ⁴Nagoya City University Graduate School of Medical Science, Japan, ⁵International Research Center for Neurointelligence (WPI-IRCN), Japan

PS01.69 The Case of Severe Alprazolam Addiction

Olena Pityk
Ivano-Frankivsk National Medical University, Ukraine

PS01.70 Socio-demographic and clinical variables associated with the implementation of add-on treatment strategies in unipolar depression – a naturalistic European multicenter investigation

Markus Dold¹, Lucie Bartova¹, Alessandro Serretti², Joseph Zohar³, Daniel Souery⁴, Julien Mendlowitz⁵, Stuart Montgomery⁶, Siegfried Kasper¹
¹Medical University of Vienna, Austria, ²University of Bologna, Italy, ³Sheba Medical Center, Israel, ⁴Centre Européen de Psychologie Médicale, Belgium, ⁵Free University of Brussels, Belgium, ⁶University of London, UK

PS01.71 Antidepressive therapy has no effect on criiliary neurotrophic factor concentration in blood serum of patients with melancholic depression

Marat Uzbekov, Sergej Shikhov
Moscow Research Institute of Psychiatry, Russian Federation
PS02.06 Specific psychiatric symptoms, social functions, and pharmacotherapy of Japanese adult outpatients with neurodevelopmental disorders

Hiromitsu Uno, Osamu Takashio, Marie Ota, Ayaka Sato, Yousuke Sawanobori, Hideaki Kawai, Mari Yamada, Yukinori Kamata, Tomohiro Yoshida, Haruka Yanagihara, Shutaro Sugita, Tomoyuki Tachibana, Akira Iwanami
School of Medicine, Showa University, Japan

PS02.07 Delayed maturation hypothesis in SHR model of ADHD in terms of brain network topology

Soomin Jang1, Yebin D Ahn1, Narae Yoon1, Chanmo Yang1, Jaewon Song1, Seunggyun Ha2, Bung-Nyun Kim1
1Seoul National University Hospital, South Korea, 2Seoul National University College of Medicine, South Korea

PS02.08 Peripheral mitochondrial DNA copy numbers are increased in Korean attention-deficit hyperactivity disorder

Yebin D Ahn, Soomin Jang, Jung Lee, Chanmo Yang, Gahye Noh, Hyungseo Park, Inhyang Kim, Bung-Nyun Kim
Seoul National University Hospital, South Korea

PS02.09 Chronic valproic acid reduces compulsivity and contributes to choice preference toward risk in a rat gambling task

Min Jeong Ku1, Myung Ji Kwak2, Wha Young Kim2, Jeong-Hoon Kim2
1Yonsei University College of Medicine, South Korea, 2Yonsei University College of Medicine, South Korea

PS02.10 ADHD medication and behavioral and neuropsychiatric outcomes: real-world evidence from pharmacoepidemiology studies

Zheng Chang1, Laura Ghirardi1, Patrick D. Quinn2, Brian M D’Onofrio2, Henrik Larsson1
1Karolinska Institutet, Sweden, 2Indiana University, USA

---

**Topic: ADHD**

PS02.01 A Study on the School Violence Experience of Children with Attention Deficit Hyperactivity Disorder in the Context of Bullying

Sung Young Huh1, Kyung Ha Noh1
1Pusan National University Yangsan Hospital, South Korea, 2Good- Gang An Hospital, South Korea

PS02.02 Symptoms of Attention-Deficit/Hyperactivity Disorder in Korean elementary school children

Kyung Kyu Lee, Kyoungh Min Kim
Dankook University Hospital, South Korea

PS02.03 Long-Term Effects of Attention-Deficit Hyperactivity Disorder Medication on Growth in the Korean School-Aged Boys with Attention-Deficit Hyperactivity Disorder

Kanguk Lee, Junwon Hwang, Siyoung Kim
Kangwon National University Hospital, South Korea

PS02.04 Radixin in the nucleus accumbens contributes to choice preference toward risk in rat gambling task

Jong Woo Park, Myung Ji Kwak, Bo Ram Cho, Wen Ting Cai, Wha Young Kim, Jeong-Hoon Kim
Yonsei University College of Medicine, South Korea

PS02.05 Differential Activity and Functional Coupling to the Prefrontal cortex of Dopamine Neurons in the Ventral Tegmental Area in the WKY/Ncrl and SHR/Ncrl Animal Models of ADHD

Ike De La Peña, Wei-Xing Shi
Loma Linda University, USA
PS02.11 Clinical predictors of response to methylphenidate in adult Attention Deficit Hyperactivity Disorder: preliminary results from a longitudinal, naturalistic study

Ana Velosa1, J. Bernardo Barahona-Corrêa1,2,3,4
1Centro Hospitalar de Lisboa Ocidental, Portugal, 2NOVA Medical School | Faculdade de Ciências Médicas - Universidade NOVA de Lisboa, Portugal, 3Champalimaud Research and Clinical Centre, Champalimaud Centre for the Unknown, Portugal, 4CADIn: Centro de Apoio ao Desenvolvimento Infantil, Portugal

PS02.12 The associations between prenatal maternal obesity and fetal prefrontal functional connectivity

Carly Lenniger
NYU Langone Health, USA

PS02.13 Comparative Cognitive Effects of Methylphenidate, Guanfacine, and the Combination in Children with ADHD

James McCracken
UCLA Semel Institute, USA

Topic: Mood

PS02.14 Influence of anxiety symptoms on improvement of neurocognitive functions in patients with major depressive disorder: A 12-week, multicenter, randomized trial of tianeptine versus escitalopram, the CAMPION study

Dong Jun Kim1, Maurizio Fava2, David Mischoulon2, George Papakostas2, Hong Jin Jeon3
1Samsung Medical Center, South Korea, 2Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, USA, 3Samsung Medical Center, Sungkyunkwan University School of Medicine, South Korea

PS02.15 Effects of low-grade inflammation on functional brain networks

Jungyoon Kim1,2, Su Jung Yoon1,2, Ga Hae Hong1, Yoonji Joo1, Jin Soo Kim1, Yoonsoo Kim1, In Kyoon Lyoo1,2,3,4
1Ewha Brain Institute, Ewha W. University, South Korea, 2Department of Brain and Cognitive Sciences, Ewha W. University, South Korea, 3Graduate School of Pharmaceutical Sciences, Ewha W. University, South Korea, 4The Brain Institute and Department of Psychiatry, University of Utah, USA

PS02.16 A data-driven approach to the identification of risk factors for future addictive disorder: network-based neurobiological model for predicting addiction-proneness

In Kyoon Lyoo1,2,3,4, Sung Yoon1,2, Jungyoon Kim1,2, Ga Hae Hong1, Tamny D. Kim1,2, Jinsol Kim1,2, Yoonji Joo1,2, Yoonsoo Kim1
1Ewha Brain Institute, Ewha W. University, South Korea, 2Department of Brain and Cognitive Sciences, Ewha W. University, South Korea, 3Graduate School of Pharmaceutical Sciences, Ewha W. University, South Korea, 4The Brain Institute and Department of Psychiatry, University of Utah, USA

PS02.17 Investigation of Selected microRNA in a Chronic Mild Stress Model

Louise Sand Kirke, Birgitte Hvid Mumm, Lena-Sophie Martins, Ove Wiborg, Betina Elfving
Translational Neuropsychiatry Unit, Aarhus University, Denmark

PS02.18 - Dysmorphophobia: Evolution or Involution?

Clara Sanahuja Muñoz
Hospital Universitario la Princesa, Spain

PS02.19 An in silico analysis to prioritise genes co-expressed with the serotonin-1A receptor using PET and Allen Human Brain Atlas data

Jakob Unterholzner1, Gregor Gryglewski2, Cecile Philippe1, René Seiger1, Verena Pichler1, Godber Mathis Godbersen2, Neydher Berrotaran-Infante3, Andreas Hahn3, Wolfgang Wadsak3,4, Markus Mitterhauser3,4, Siegfried Kasper2, Rupert Lanzenberger2
1Medical University of Vienna, Austria, 2Department of Psychiatry and Psychotherapy, Medical University of Vienna, Austria, 3Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Austria, 4Centre for Biomarker Research in Medicine (CBmed), Austria, 5Ludwig Boltzmann Institute Applied Diagnostics, Austria
PS02.20 Pharmacological treatment of 124,404 patients diagnosed with major depressive disorder at Danish psychiatric hospitals in the period from 1995 to 2016
Soren Dinesen Oestergaard1, Christiane Gasse1, Liselotte Petersen2, Rune Haubo Christensen2, Fredrik Hieronymus3, Ole Köhler-Forsberg1
1Department of Psychiatry, Aarhus University Hospital, Denmark,2Center for Register-based Research, Aarhus University, Denmark,3Mental Health Center Copenhagen, University of Copenhagen, Denmark,4Department of Clinical Medicine, Aarhus university, Denmark

PS02.21 Greater right frontal activity and its related symptom severity in manic patients
Vin Ryu, You Seok Kim
National Center for Mental Health, South Korea

PS02.22 Chronic restraint stress-induced depression-like behavior is mediated by up-regulation of melanopsin expression in C57BL/6 mice retina
Yingmei Fu1, Shunying Yu2, Qingqing Xu2, Yi Dong3
1Shanghai Key Laboratory of Psychotic Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, China, 2Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, China, 3Key Laboratory of Adolescent Health Assessment and Exercise Intervention of Ministry of Education, East China Normal University, China

PS02.23 Factors associated with the severity of treatment refractory depression
Kazuhiro Nozaki1, Yoshikazu Takaesu2, Yayoi Imamura1, Takeshi Katagiri1, Yuta Kanda1, Takashi Tuboi1, Koichiro Watanabe1
1Kyorin University School of Medicine, Japan, 2Kyorin University, Japan

PS02.24 Evaluation of a5 GABA-NAMs in animal models of depression
Astrid Hylgaard Bach, Claudia Regina Cecchi, Gregers Wegener, Betina Elfving
Translational Neuropsychiatry Unit, Department of Clinical Medicine, Aarhus University, Denmark

PS02.25 Patterns of Protein Expression and Correlation in Mononuclear Blood Cells for Lithium Treatment Response of Bipolar Disorder: a Flow Cytometry Study
Keming Gao1, Joseph Calabrese1, Stephen Ganocy9, Nicholas Kaye2, Hillard Lazarus1, David Kaplan2
1Case Western Reserve University/University Hospitals Cleveland Medical Center, USA, 2CellPrint, USA

PS02.26 Ketamine modulates striatal activity to reward magnitude 2 hours after its administration: an fMRI study in unmedicated, remitted depressed volunteers
Vasileia Kotoulia1, James Stone1, Argyris Stringaris2, Val Curran3, Mitul Mehta1
1Centre for Neuroimaging Sciences, IoPPN, King’s College London, UK, 2Mood Brain and Development Unit, Emotion and Development Branch, National Institute of Mental Health, National Institutes of Health, USA, 3Clinical Psychopharmacology Unit, Research Department of Clinical, Educational and Health Psychology, University College London, UK

PS02.27 Proof of concept for a newly identified target, 11-beta-hydroxysteroiddehydrogenase type 2, to treat therapy refractory depression – the effect of glycyrhizin on treatment outcome
Harald Murck, Lisa Lehr, Maxim Zavorotnyy, Tilo Kircher
Psychiatric Clinic of the Philipps-University Marburg, Germany

PS02.28 Another view at the Major Depressive Disorder biomarkers
Michaela Krivosova1, Marian Grendar2, Ingrid Tonhajzerova3, Igor Hrtanek1, Petra Kosutova3, Nikola Sekaninova2, Igor Ondrejka3, Patrik Kusnir1, Juraj Mokry6
1Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Slovak Republic, 2Bioinformatics Unit, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Slovak Republic, 3Biomedical Centre Martin, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Slovak Republic, 4Psychiatric Clinic, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin University Hospital, Slovak Republic, 5Department of Physiology, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Slovak Republic, 6Biomedical Centre Martin, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Slovak Republic
PS02.29 Brain SPECT Pre-Post Magnetic Seizure Therapy (MST) for Major Depressive Disorder as a Marker of Remission
Fatma El-Deeb1, El-Sayed Gad1, Ahmed Kandeel1, Amr Haiba1, Sameh Sadek1, Meghan Peterson1, Nagy Youssef2
1Tanta University, Egypt, 2Cairo University, Egypt, 3Medical College of Georgia at Augusta University, USA

PS02.30 Bearing of maternal prenatal stress on the developing fetal brain and timing of delivery
Moriah Thomason
New York University Medical Center, USA

PS02.31 Double-Blinded Randomized Pilot Clinical Trial Comparing Cognitive Side Effects & Antidepressant Efficacy of Standard Right Unilateral ECT versus Low Amplitude Seizure Therapy (LAP-ST)
Nagy Youssef1, Dheeraj Ravilla, William McCall, Laryssa McCloud, Peter Rosenquist
Medical College of Georgia at Augusta University, USA

PS02.32 Adjunctive antidepressant treatment for acute bipolar depression: Findings from the Bipolar CHOICE trial
Ole Kühler-Forsberg1,2, Andrew Nierenberg2
1Aarhus University Hospital, Denmark, 2Massachusetts General Hospital, USA

PS02.33 Effect of combined treatment with SSRIs and renin-angiotensin system (RAS) drugs: Population-based and propensity-score matched cohort study
Ole Kühler-Forsberg1, Søren Dinesen Østergaard, Christiane Gasse
Aarhus University Hospital, Denmark

PS02.34 Clinical correlates of comorbid hypertension in patients with major depression
Gernot Fugger1, Markus Dold1, Lucie Bartova1, Alexander Kautzky1, Daniel Souery2, Julien Mendlewicz1, Alessandro Serretti4, Joseph Zohar3, Stuart Montgomery1, Richard Frey1, Siegfried Kasper3
1Medical University of Vienna, Austria, 2Centre Européen de Psychologie Médicale, Brussels, Belgium, 3Free University of Brussels, Belgium

PS02.35 Pharmacogenomics in the Service of Personalized Psychopharmacology
Angelos Halaris
Loyola University Stritch School of Medicine, USA

PS02.36 Comparing cognitive side effects & antidepressant efficacy of Focal Electrically Administered Seizure Therapy (FEAST) versus standard ultra-brief Right Unilateral (RUL) ECT: A two-site clinical trial
Nagy Youssef1, Mark George2, William McCall1, Greg Sahlem1, Baron Short2, Suzanne Kerns3, Morgan Dancy1, Daniel Cook2, William Devries3, Peter Rosenquist1, Harold Sackeim1
1Medical College of Georgia at Augusta University, USA, 2Medical University of South Carolina, USA, 3Columbia University, USA

PS02.37 Comparison of serum microbiome composition between bipolar disorder and major depressive disorder
Sang Jin Rhee1, Hyeyeong Kim2, Yunna Lee3, Hyun Jeong Lee4, C. Hyung Keun Park1, Jinho Yang1, Yoon Keun Kim1, Yong Min Ahn1
1Seoul National University Hospital, South Korea, 2Inha University Hospital, South Korea, 3Mental Health Clinic, National Cancer Center, South Korea, 4MD Healthcare Inc., South Korea

PS02.38 The Combination Therapy of ECT and Aripiprazole for Treatment Resistant Schizophrenia with Dopamine Supersensitivity Psychosis
Masahiko Nishimoto, Kengo Miura, Keiichiro Tomiyama, Fumio Kohda, Kiyohi Sekiguchi, Hirofumi Wakatabe, Takashi Kuroiwa
SouShu Hospital, Japan
Topic: Other

PS02.39 Two-sample Mendelian randomization study for schizophrenia and breast cancer
Woojae Myung¹, Soyeon Kim², Hong-Hee Won²
¹Seoul National University Bundang Hospital, South Korea, ²Samsung Advanced Institute for Health Sciences and Technology (SAIYST), South Korea

PS02.41 Treatment satisfaction with paliperidone palmitate in patients with current oral atypical antipsychotics
Geli Marie Chauca Chauca, Laura Carrión
Exposito, Rosa Maria Galán Armenteros Hospital Infanta Margarita, Spain

PS02.42 Dysregulated insulin family member expression is associated with adult neurogenesis and inflammation in the human subependymal zone in schizophrenia and bipolar disorder
Christin Weissleder¹,², Hayley F. North¹,², Maree J. Webster³, Cynthia Shannon Weickert¹,²,⁴
¹Schizophrenia Research Laboratory, Neuroscience Research Australia, Australia, ²School of Psychiatry, Faculty of Medicine, University of New South Wales, Australia, ³Laboratory of Brain Research, Stanley Medical Research Institute, USA, ⁴Upstate Medical University, USA

PS02.43 20-year follow-up study on antipsychotic treatment, physical morbidity, and mortality in a nationwide cohort of 62,250 patients with schizophrenia (FIN20)
Jari Tiihonen¹, Antti Tanskanen², Juha Mehtälä³, Pia Vattulainen¹, Christoph U Correll⁴, Heidi Taipale²
¹Karolinska Institutet, Sweden, ²University of Eastern Finland, Niuvanniemi Hospital, Finland, ³Epid Research Oy, Finland, ⁴The Zucker Hill Hospital, USA

PS02.44 Development Update on Pimavanserin, a 5-HT2A Receptor Inverse Agonist
Dragana Bugarski-Kirola¹, Randy Owen¹, Bryan Dirks¹, Erin Foff¹, James Youakim¹, Doral Fredericks², Srdjan Stankovic¹
¹ACADIA Pharmaceuticals Inc., USA, ²ACADIA Pharmaceuticals Inc., USA

PS02.45 Delayed effect of NMDA receptor blockade on forebrain network oscillations in rats
Linn Jansson, Carolina Wilnerzon Thorn, Bernat Kocsis
Dept Psychiatry-BIDMC, Harvard Medical School, USA

PS02.46 Respiratory synchrony in the acute ketamine model of schizophrenia in rats
Rola Mofleh, Bernat Kocsis
Dept Psychiatry-BIDMC, Harvard Medical School, USA

PS02.47 Patterns of Antipsychotic Medication Prescribing in Australia
Nagesh Pai¹,², Judy Mullan², Mustafa Acar³, Prabhjot Junea³, Mahsa Kouhkamari³,²,⁴, Sinthuja Siva³
¹Illawarra Shoalhaven Local health district, Australia, ²University of Wollongong, Australia, ³Prospection Pty Ltd, Australia, ⁴Prospections, Australia

PS02.48 Patient Persistence on Antipsychotic Medications in Australia
Nagesh Pai¹,², Judy Mullan², Mustafa Acar³, Prabhjot Junea³, Mahsa Kouhkamari¹, Sinthuja Siva³
¹Illawarra Shoalhaven Local health district, Australia, ²University of Wollongong, Australia

PS02.49 Sex-specific transcriptional and proteomic signatures in schizophrenia
Jari Tiihonen¹, Marja Koskuvi², Markus Storvik³, Ida Hyötyläinen², Yanyan Gao³, Katja Puttonen², Raisa Giniatullina², Ekaterina Poguzhelskaya³, Ilkka Ojansuu², Olli Vaorio³, Tyrone D Cannon⁴, Jouko Lönnqvist³, Sebastian Therman³, Jaana Suvisaari³, Jaakko Kaprio⁴, Lesley Cheng⁵, Andrew Hill⁶, Markku Lähteenvuor⁶, Jussi Tohka³, Rashid Giniatullin³, Sarka Lehtonen⁶, Jari Koistinaho⁶
¹Karolinska Institutet, Sweden, ²University of Eastern Finland, Finland, ³Niuvanniemi Hospital, Finland, ⁴Yale University, USA, ⁵National Institute for Health and Welfare, Finland, ⁶University of Helsinki, Finland, ⁷La Trobe Institute for Molecular Science, Australia
PS02.50 Vortioxetine for negative symptoms of schizophrenia: from theory to practice
Antonios Paraschakis
Psychiatric Hospital of Attica "Dafni", Greece

PS02.51 Management of risperidone-induced hyperprolactinaemia
Anastasia Kokkali, Aikaterini Kalogeropoulou
Dromokaitete Psychiatric Hospital, Greece

PS02.52 Impact of a GWAS SNP in MIR137 on neurodevelopment in a novel CRISPR mouse model for schizophrenia
Mengyi Xu1, James Samsom1, Amy Freeman2, Felix Wong1, Albert Wong1
1Centre For Addiction and Mental Health, Canada, 2University of Toronto, Canada

PS02.53 Striatal Glutamatergic Levels and their Apparent Upregulation in First-episode Psychosis Patients: A Pilot In Vivo 1H MRS Study
Dikoma Shungu1, Francisco Reyes-Madrigal2, Pablo León-Ortiz2, Xiangling Mao1, Ricardo Mora1, Camilo De La Fuente-Sandoval1
1Weil Cornell Medicine, USA, 2Instituto Nacional de Neurología y Neurocirugía, Mexico

PS02.54 An Approach to reaction time in patients suffering from schizophrenia
Ioannis Apostolopoulos
DROMOKAITTIO, Greece

PS02.55 Two novel loci associated with antipsychotics response in Chinese Han population
Qingqing Xu, Yingmei Fu, Shunying Yu
Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, China

PS02.56 Population Coding of Multiple Types of Information in Dentate Gyrus
Ryuichi Nakajima1, Tomoyuki Murano1, Akito Naka1, Nao Hirata1, Satoko Amemori1, Akira Murakami1, Yukiyasu Kamitani1, Jun Yamamoto1, Tsuyoshi Miyakawa1
1Division of Systems Medical Science, Institute for Comprehensive Medical Science, Fujita Health University, Japan, 2Graduate School of Engineering, Kyoto University, Japan, 3Graduate School of Informatics, Kyoto University, Japan, 4Neuroscience Division, Southwestern Medical Center, The University of Texas, USA

PS02.57 12-month Greek prospective non-interventional multicenter study for early stage schizophrenia treatment with once monthly Paliperidone Palmitate
Konstantinos Samaras1, Nikos Chalarakis2, A Voulgaraki3, Vasilleios Kladouchos4, Robert Wapenaar5, Theofilos Stergiou6, Grigoris Koueni6, Niou Setta-Kafletzi2, Athanasios Piachas2, Dimitrios Kyriakos, Mario Zittis4, Konstantina Sotiriadou6, Christina Kalkavoura4, Georgios Pagkalos7, Eirini Papagavriil7, Georgios Tzefarakos4, Eva-Maria Tsapakis8, Petros Fotiadis9
1Janssen-Cilag Pharmaceutical SACI, Greece, 2Janssen-Cilag Pharmaceutical SACI, Greece, 3Private Practice, Greece, 4Private Practice, Greece, 5Janssen-Cilag BV, Netherlands, 6Private Practice, Greece, 7Private Practice, Greece, "Aghios Charalambos" Mental Health Clinic, Greece

PS02.58 Dopamine signaling and dyslipidemia in first episode psychosis
Irene Graf1, Ana Weidenauer1, Ulrich Sauerzopf2, Irena Dajić3, Verena Pichler1, Sarah Pfaff1, Lukas Nics3, Thomas Scherer4, Michael Krebs4, Rupert Lanzenberger1, Siegfried Kasper1, Nicole Praschak-Rieder1, Wolfgang Wadsak1, Matthäus Willeit1
1Department of Psychiatry and Psychotherapy, Division of General Psychiatry, Medical University of Vienna, Austria, 2Department of Psychiatry and Psychotherapy, Division of General Psychiatry, Medical University of Vienna, Austria, 3Department of Biomedical Imaging and Image Guided Therapy, Medical University of Vienna, Austria, 4Department of Medicine III, Division of Endocrinology and Metabolism, Medical University of Vienna, Austria
PS02.59 Functional coupling between M1 muscarinic acetylcholine receptors and Galphα(q/11) proteins distortedly distributed only in schizophrenic patients: A postmortem study
Yuji Odagaki1, Masakazu Kinoshita1, J. Javier Meana2, Luis F. Callado2, Jesús A. García-Sevilla3
1Saitama Medical University, Japan, 2University of the Basque Country, UPV/EHU, Spain, 3Laboratory of Neuropharmacology, IUNICS/IdISPa, University of the Balearic Islands (UIB), Spain

PS02.60 XEUS STUDY: A non-interventional, multicenter, retrospective study of schizophrenic patients treated with Paliperidone Palmitate Once Monthly in Greece
Dimos Dimellis1, Konstantinos Samaras3, Filippis Kouniakis1, Christos Tsaltas3, Eva-Maria Tsapakis4, Nikos Chalarakis5, Dimitrios Xomalis6, Petros Fotiadis7, Niovi Setta-Kaffetzi8, Theodoros Mougiakos8, Nikolaos Gouvas8, Fani Patriki8, Achilleas Oikonomou9, Nikolaos Kokras9, Grigoriou Konenis9, Vasiliki Psarra9, Georgios Alevizopoulos11, Vasileios Panteleimon Bozikas12
1"Ego Ideal” Private Institute of Mental Health, Greece, 2Janssen-Cilag Pharmaceutical SACI Greece, 3Agios Nikitas” Psychiatric Clinic, Greece, 4Aghios Charalambos” Mental Health Clinic, Greece, 5Janssen-Cilag Pharmaceutical SACI, Greece, 6Private Practice, Greece, 7Private Practice, Greece, 8Private Practice, Greece, 9Psychiatric Hospital of Attiki, Greece, 10University Clinic of General Oncological Hospital of Kifissia, Greece, 11Aristotle University of Thessaloniki, Greece

PS02.61 The efficacy and safety of brexipiprazole in Japanese patients with schizophrenia at acute phase; A retrospective study
Yasutaka Fujita, Keigo Nakatsu, Yumi Agari, Yoko Iwasaki, Hiroki Yada, Goro Sato
Kusatsu Hospital, Japan

PS02.62 Obesity, psychosis and lower grey matter volumes in cerebellum
Marian Kolenic1,2, Jaroslav Hlinka1, Pavel Knýt1,2, Jirka Renka1,2, Antonin Sebela1, Filip Spaniel1, Tomas Hajek4
13rd School of Medicine, Czech Republic, 2National Institute of Mental Health, Czech Republic, 3Institute of Computer Science, Czech Republic, 4Dalhousie University, Canada

PS02.63 Improved of negative symptoms and metabolic rates in schizophrenic patients treated with paliperidone palmitate long-acting injection
Eugenio Suarez Gisbert
University Hospital Infanta Sofia San Sebastian De Los Reyes, Spain

PS02.64 Evaluation of bone demineralization risk in patients with iatrogenic hyperprolacminemia by antipsychotics: preliminary data
Angel Luis Montejo, José Maria Acosta, Nieves Prieto, Teresa Notario, Tomás Martín-Pinto, Santiago Sánchez-Iglesias, José López, Berta Bote, Teresa Gallego, Angel Martin, Barbara Buch
University of Salamanca, Spain

PS02.65 A case of Ekbom Syndrome successfully treated with aripiprazol
Eugenio Suarez Gisbert1, Maria Jose Abenza2
1Psychiatric Department, University Hospital Infanta Sofia San Sebastian De Los Reyes, Spain, 2Neurology Department, University Hospital Infanta Sofia San Sebastian De Los Reyes, Spain

PS02.66 Moral judgment and social-emotional cognition in paranoia
George J Savulich1, Trevor W. Robbins2, Barbara J. Sahakian1
1University of Cambridge, Department of Psychiatry and Behavioural and Clinical Neuroscience Institute, UK, 2University of Cambridge, Department of Psychology, UK

PS02.67 Evaluation of a Novel Point of Care Testing Device for Rapid Measurement of Clozapine in Whole Blood
David Taylor1, Matthew Atkins2, Philip Mcguire1, Salvatore Salamone3, Irina Baburina1
1King’s College, UK, 2Maudsley Hospital, UK, 3Salada Biomedical, USA

PS02.68 Increased matrix metalloproteinase-9 and prefrontal deficits in schizophrenia
T. Wilson Woo1,2,3, Katina Athanas3
1Beth Israel Deaconess Medical Center, USA, 2Harvard Medical School, USA, 3McLean Hospital, USA
PS02.69 Long-acting injectable aripiprazole for an elderly patient with concomitant delusional disorder and mild dementia
I-Chun Lee
Hualien Tzu Chi Hospital, Taiwan

PS02.70 Comparison the effectiveness of long-acting injections of second generation antipsychotic
Eugenio Suarez Gisbert
University Hospital Infanta Sofia, Spain

Topic: ADHD

PS02.71 Sydnocarb treatment has revealed kynurenine involvement in pathogenetic mechanisms of attention deficit hyperactivity disorder
Marat Uzbekov¹, Yuli Misionzhnik¹, Sergej Shikhov¹, Natalia Smolina¹, Irina Strelkova¹, Varvara Brilliantova¹, Dinara Uzbekova²
¹Moscow Research Institute of Psychiatry, Russian Federation, ²Ryazan State Medical University, Russian Federation
Badges
A personalised badge will be provided to you during check-in at the registration desk. For logistical and security reasons, badges will need to be worn at all times. In case of a badge loss, a replacement will be provided for an administrative charge of EUR 15.

Cameras and Cell Phones
No cameras or video cameras are allowed in any event during CINP 2019. As a courtesy to fellow delegates, please turn off cell phones during scientific sessions.

CME Accreditation
The 2019 CINP International Meeting has been granted 20 CME credits by The European Accreditation Committee in CNS (EACIC).

To obtain your CME credits, fill out the evaluation form after the Meeting on www.eacic.eu The event login code is CINP2019

An electronic evaluation form will be emailed to you after the meeting. Attendees who wish to receive certificate of participation will have to complete the online evaluation form. The Certificate of Attendance will be emailed upon completing the survey.

Networking Breaks and Lunches
Networking breaks and lunches will take place in the Olympia Foyer of the Royal Olympic Hotel.

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thursday 3 October</td>
<td>10:00 - 10:30</td>
</tr>
<tr>
<td></td>
<td>12:00 - 13:00</td>
</tr>
<tr>
<td></td>
<td>15:30 - 16:00</td>
</tr>
<tr>
<td>Friday 4 October</td>
<td>10:00 - 10:30</td>
</tr>
<tr>
<td></td>
<td>12:00 - 13:30</td>
</tr>
<tr>
<td></td>
<td>16:00 - 16:30</td>
</tr>
<tr>
<td>Saturday 5 October</td>
<td>10:00 - 10:30</td>
</tr>
<tr>
<td></td>
<td>13:30 - 14:30</td>
</tr>
</tbody>
</table>

Guided Poster Sessions
Poster sessions will be held in the Olympia Foyer on Thursday 3 and Friday 4 October from 17:30 to 18:30. See the programme of posters on pages 23-38.

Internet
Complimentary wireless internet is available to all delegates throughout the venue.

Network name: Royal Olympic
Password: royal2019

Disclaimer
Meeting organisers cannot accept any liability for the acts of the suppliers to this meeting or the attendees’ safety while travelling to or from the Meeting. All participants are strongly advised to carry adequate travel and health insurance, as Meeting organisers cannot accept liability for accidents or injuries that may occur.

Meet the Expert Sessions
For more details about the Meet the Expert sessions presented by CINP 2019 sponsors please refer to page 41.
Meeting Secretariat
International Conference Services (ICS) GmbH
Nußdorfer Straße 20/24, 1090 Vienna, Austria
Email: cinp2019@cinp.org
Web: www.icsevents.com

Meeting Venue
Royal Olympic Hotel
Athanasiou Diakou 28, Athens, Greece 117 43
Email: info@royalolympic.com
Web: www.royalolympic.com

Mobile App
Plan your own CINP 2019 schedule. Browse sessions by track, date, and time. Interact with colleagues.

The meeting app also includes all abstracts submitted and accepted for presentation at CINP 2019.

Smoking
CINP 2019 is a non-smoking meeting. Smoking is prohibited in all areas of the Royal Olympic Hotel.

Speaker Ready Room
Alexander Hall is the designated Speaker Ready Room. All presenters are required to upload their slides at least 2 hours prior to their scheduled session to ensure compatibility with the meeting AV equipment. Changes can be made until 60 minutes prior to the session. Presenters should make sure all fonts appear as expected and all sound/video clips are working properly.
No file submissions are accepted in the session rooms. Speakers are not allowed to use their own laptops for their presentations.

Speaker Ready Room Hours

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wednesday 2 October</td>
<td>17:00 - 19:00</td>
</tr>
<tr>
<td>Thursday 3 October</td>
<td>07:00 - 16:00</td>
</tr>
<tr>
<td>Friday 4 October</td>
<td>08:00 - 16:00</td>
</tr>
<tr>
<td>Saturday 5 October</td>
<td>08:00 – 12:30</td>
</tr>
</tbody>
</table>

Posters
Poster presenters who ordered poster print and delivery from the official supplier of CINP 2019, are requested to collect their poster from the Registration Desk during its opening hours.

<table>
<thead>
<tr>
<th>Day</th>
<th>Set-up</th>
<th>Take-down</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thursday posters</td>
<td>Thursday 3 October</td>
<td>Thursday 3 October after 18:30</td>
</tr>
<tr>
<td>hours</td>
<td>07:30 - 09:30</td>
<td></td>
</tr>
<tr>
<td>Friday posters</td>
<td>Friday 4 October</td>
<td>Friday 4 October after 18:30</td>
</tr>
<tr>
<td>hours</td>
<td>07:30 - 09:30</td>
<td></td>
</tr>
</tbody>
</table>

Any posters not removed by Saturday morning 5 October will be discarded by management.

Please check your assigned poster number on the meeting website or on the mobile app.

Registration Desk Hours
CINP 2019 registration counters are located in the Olympia Foyer.

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wednesday 2 October</td>
<td>17:00 – 19:00</td>
</tr>
<tr>
<td>Thursday 3 October</td>
<td>07:00 - 17:00</td>
</tr>
<tr>
<td>Friday 4 October</td>
<td>08:00 - 18:00</td>
</tr>
<tr>
<td>Saturday 5 October</td>
<td>08:00 – 13:30</td>
</tr>
</tbody>
</table>

Showcase Presentations
Special showcase presentations will take place in the showcase theatre located in the Olympia Foyer during the networking breaks. For detailed programme please refer to pages 42.
Meet the Expert Sponsored Sessions

Thursday 3 October 2019
13:00 - 14:30
Location: Attica Hall

Time to act in major depressive disorder (MDD)

Speakers:
Siegfried Kasper, Daniel Souery, Andreas Papadopoulos, Lucie Bartova, Andrew J. Cutler

13:00 - 13:05
Welcome & Introduction
Chair: Siegfried Kasper, Austria

13:05 - 13:45
When to act: Optimising treatment in MDD
Daniel Souery, Belgium
Andreas Papadopoulos, UK

13:45 - 14:25
How to act: Are fast-acting treatments the future?
Lucie Bartova, Austria
Andrew J. Cutler, USA

14:25 - 14:30
Close
Chair: Siegfried Kasper, Austria

Presented by Janssen

Saturday 5 October 2019
10:00 - 12:00
Location: Templar’s Hall

Discovering ADHD in Adults

Speakers:
Susan J. Young, UK
Larry J. Klassen, Canada
Josep Antoni Ramos-Quiroga, Spain.

Presented by Takeda
How do you approach the treatment of depressive episodes today? What pathways are thought to play a role in depression?

Speaker: Celso Arango, Spain

Presented by Sage Therapeutics

Antipsychotic POCT for medication adherence and blood level monitoring

Speaker: David Taylor, UK

Presented by Saladax Biomedical

Optimising treatment outcomes in major depressive disorder (MDD)

Scientific committee: Siegfried Kasper, Austria

Moderator: Siegfried Kasper, Austria

Speakers:
Lucie Bartova, Austria

16:10–16:13 Characterisation of the MDD patient
Lucie Bartova, Austria

16:13–16:20 Current challenges of when and how to treat
Lucie Bartova, Austria

16:20–16:25 Moderated Q&A session
Moderator: Siegfried Kasper, Austria
Lucie Bartova, Austria

Presented by Janssen
www.biopac.com
BIOPAC provides solutions for all your research and educational data acquisition requirements. The sophisticated high-speed MP160 system has 20+ amplifier options, including noninvasive cardiac output, noninvasive BP, stimulus presentation and Virtual Reality. Standardize results and save time with automated analysis tools, including ECG, EEG, EMG, EDA, HRV, RSA, bioimpedance, BP, LVP, and spike sorting.

www.cinp.org
The International College of Neuropsychopharmacology (CINP) (Collegium Internationale Neuro-Psychopharmacologicum) is a truly worldwide organization established over 60 years ago in Zurich, Switzerland and can count on a widespread support from all over the world by its active members. Holding regular meetings in form of Training, Educational Programs, International Meetings and World Congresses, CINP reaches interested researchers all over the world. Clinicians hear about the latest research advances and new treatments whilst researchers hear about new clinical needs and problems. Therefore, CINP is dedicated to promoting research and education on a worldwide basis.
md.catapult.org.uk
Medicines Discovery Catapult is a national facility connecting the UK community to accelerate innovative drug discovery. We provide unique scientific capabilities and act as a gateway to UK resources and expertise, supporting UK SMEs to drive the development and industrialisation of new approaches for the discovery of new medicines. By validating new ways of discovering medicines and driving key talent and expertise across the sector, we will support the UK life sciences industry, SMEs and innovators to deliver growth for the UK economy and maintain the UK’s heritage position as a global leader in medicines R&D. Ultimately, new industrialised technologies are vital for delivering new medicines to patients, faster.

www.mycaretests.com
Saladax develops rapid blood tests for point of care and for laboratory analysers. The Saladax MyCare Psychiatry line provides drug levels for greater insight into patient adherence and possible treatment failures. These tests enable psychiatrists to better assess adherence and better adjust dosing. Saladax believes that truly personalized medicine can only exist when the right drug is taken at the right dose. Our diagnostic reagent kits are distributed worldwide and are pending approval in the United States. Saladax is ISO 13485:2003 certified.

www.wisepress.com
Wisepress.com, Europe’s leading conference bookseller, has a complete range of books and journals relevant to the themes of the meeting. Books can be purchased at the stand or, if you would rather not carry them, posted to you – Wisepress will deliver worldwide.
Meeting Sponsors

The 2019 CINP International Meeting would like to thank the following companies for their generous support:

Silver Level

Janssen

Bronze Level

Sage Therapeutics

Takeda

General Sponsor

Saladax Biomedical

Educational Grant

This program is supported by an educational grant from Sunovion Pharmaceuticals Inc. and Sumitomo Dainippon Pharma Co. Ltd.
### Author Index

**A**
- Abenza Maria Jose ........................................ PS01.44, PS02.65
- Acar Mustafa ................................................. PS02.47, PS02.48
- Acosta José Maria ........................................ PS02.64
- Agari Yumi .................................................. PS02.61
- Ahn Yebin D ................................................ PS01.47, PS02.07, **PS02.08**
- Ahn Yong Min .............................................. PS02.37
- Ahn Ys ................................................................ PS01.59
- Aigner Martin ................................................ PS01.28
- Alevizopoulos Georgios ................................ PS02.60
- Alisabet Clain ............................................... PS01.36
- Alizadeh Sara ................................................ PS01.17
- Amemori Satoko ........................................ PS02.56
- Andersen Sanne ........................................ PS01.38
- Angela Pisoni .............................................. PS01.36
- An Ji Hyun .................................................... PS01.34
- Apostolopoulos Ioannis .................................. PS02.54
- Arango Celso ................................................ **SP01.1**
- Arponen Evelina .......................................... PS01.46
- Artigas Frances ............................................. **S01.1**
- Athanas Katina ............................................ PS02.68
- Atkins Matthew ........................................... PS02.67

**B**
- Baburina Irina ............................................. PS02.67
- Bach Astrid Hyldgaard ................................ PS02.24
- Baek Kwangyeol ......................................... PS01.46
- Bai Ya Mei .................................................. **PS01.01**
- Barahona-Corrêa J. Bernardo ...................... PS02.11
- Baranenko Denis .................................. PS01.21, PS01.22
- Bartova Lucie ................................................ **MTE02.3a**, PS01.70, PS02.34, **SP03.1**, **SP03.2**
- Bernegger Alexandra ................................ PS01.28
- Berroterán-Infante Neydher ...... PS01.64, PS02.19
- Besinas Argyrios ......................................... S05.1
- Bi Guo-Ha .................................................... PS01.50
- Bjerg Bendsen Birgitte ................................ PS01.07
- Blier Pierre .................................................. **KL06.1**, **WS03.1**
- Blumberg Hilary ........................................ PS01.06
- Borentain Stephane ................................ PS01.03
- Bote Berta .................................................... PS02.64
- Bozikas Vasileios Panteleimon .................. PS02.60
- Brilliantova Varvara ................................ PS02.71
- Broșen K ...................................................... PS01.24
- Buch Barbara ................................................ PS02.64
- Buck Tristram .............................................. PS01.50
- Buesa Carlos ............................................... PS01.48
- Bugarski-Kirola Dragana ......................... **PS02.44**

**D**
- Dajić Irena ................................................ PS02.58
- Damgaard Christian ................................. PS01.38
- Dancy Morgan ........................................ PS02.36
- Danyeli Lena .............................................. PS01.17
- Davis Robert ............................................... PS01.14
- Dayal Rachna ............................................. PS01.03
- De La Fuente-Sandoval Camilo ................. PS02.53
- De La Peña Ike ........................................... **PS02.05**
- Deligiannidis Kristina .......................... PS01.08, PS01.09
- Deng Chao .................................................. **PS01.26**
- Deng Zhi-De .............................................. **WS01.4**
- Devries William ....................................... PS02.36

---

Presentations highlighted in bold

= presenting author for this abstract

---

Bullock Roger ............................................. **PS01.48**

---

**C**
- Caffino Lucia ............................................ **PS01.20**
- Cai Wen Ting ........................................... **PS02.04**
- Calabrese Joseph ...................................... **PS02.25**
- Callado Luis F ......................................... PS02.59
- Cambioli Luca ......................................... PS01.18
- Cannon Tyrone D ................................ PS02.49
- Carlberg Laura ........................................ PS01.28
- Carrión Expósito Laura ......................... PS02.41
- Carrubba Erin ........................................ PS01.06
- Cecchi Claudia Regina ......................... PS02.24
- Chalarakis Nikos ................................ PS02.57, PS02.60
- Chamberlain Samuel ......................... PS01.51
- Chand Tara ............................................. PS01.16
- Chang Zheng ........................................... **PS02.10**, **S04.1**
- Chatzitofis Andreas ............................. PS01.13, PS01.56
- Chauca Chauca Geli Marie ................ PS02.41
- Cheng Lesley ........................................ PS02.49
- Cho Bo Ram ........................................... PS02.04
- Cho Hana ................................................ PS01.33
- Choi Kwan Woo ..................................... PS01.33
- Choi Kyeong-Sook ................................. **PS01.59**
- Choi Soo-Hee ......................................... PS01.29
- Choi Yoobin ........................................ PS01.29
- Christensen Rune Haubo .... PS02.20
- Cipriani Andrea ...................................... **S04.3**
- Colquhoun Helen ................................ PS01.09
- Cook Daniel ........................................... PS02.36
- Cormack Francesca ............................... PS01.67
- Correll Christoph U ....................... PS02.43
- Crean Rebecca ..................................... PS01.67
- Curran Val .............................................. PS02.26
- Cutler Andrew J .................................. **MTE02.3b**

---

---

---

---

---
Dibernardo Allitia.......................... PS01.03
Dimellis Dimos.......................... PS02.60
Dimitraka Maria.......................... S03.2
Dinesen Østergaard Søren.......... PS01.30
Dirks Bryan.......................... PS02.44
Doherty James.................. PS01.08, PS01.11, PS01.39
Dold Markus.................. PS01.18, PS01.70, PS02.34
Dong Yi............................ PS02.22
D’Onofrio Brian M.................. PS02.10
Dudnichenko Tatjana........ PS01.21, PS01.22
Dutheil Sophie........................ PS01.14

E
El Deeb Fatma.......................... S02.29
Elfving Betina................ PS01.38, PS02.17, PS02.24
Elkholu OSSama................ PS01.43, PS01.63
Elsheshai Ahmed................ PS01.43, PS01.63
Epperson C. Neill.................. PS01.09
Eriksson Elias........ KL04.1, PS01.30, PS01.62
Espinoza Mae Joy................ PS01.61
Espinoza Perry.................. PS01.61
Etsuo Susaki A.................. PS01.68
Evans Jennifer........................ WS01.2

F
Fan Siyan.......................... PS01.06
Fan Yan.......................... PS01.16, PS01.17
Fava Maurizio........ KL07.1, PS01.33, PS01.34,
.................................. PS01.35, PS01.36, PS02.14
Fedotova Julia................ PS01.21, PS01.22
Ferrer Marc.......................... PS01.48
Filip Malgorzata.................. PS01.20
Foff Erin.......................... PS02.44
Forsback Sarita.................. PS01.46
Fotiadis Petros................ PS02.57, PS02.60
Fountoulakis Konstantinos MTE03.1,
.................................. S02.2, S05.1
Frazer Alan.......................... MTE01.1
Fredericks Doral.................. PS02.44
Fredricson Overo Kerstin.......... PS01.24
Freeman Amy.................. PS02.52
Frey Richard.................. PS02.34
Friedrich Michaela-Elena......... PS01.18
Fugger Gernot.................. PS02.34
Fujita Yasutaka................ PS02.61
Fukuda Masato........ PS01.02, PS01.10, PS01.12
Fumagalli Fabio................ PS01.20
Fu Yingmei........................ PS02.22, PS02.55

G
Gad El-Sayed.......................... PS02.29
Gafarova Almira.................. PS01.05
Gafarov Valery.................. PS01.05
Gagulina Igor.................. PS01.05
Galaj Ewa.......................... PS01.50
Galán Armenteros Rosa María PS02.41
Gallego Teresa.................. PS02.64
Gancay Stephen.................. PS02.25
Gao Keming........................ PS02.25
Gao Yanyan........................ PS02.49
García-Sevilla Jesús A........ PS02.59
Gardner Eliot........................ PS01.50
Gasse Christiane........ PS02.20, PS02.33
George I. Papakostas........ PS01.36
George Mark.................. PS02.36
Ghirardi Laura.................. PS02.10
Giniatullina Raisa................ PS02.49
Giniatullin Rashid........ PS02.49
Gisbert Laura.................. PS01.48
Gobbi Gabriella.......... S05.3
Godbersen Godber Mathis PS01.64, PS02.19
Gouvas Nikolaos.................. PS02.60
Graf Irene.......................... PS02.58
Grant Jon.......................... PS01.51
Grendar Marian.................. PS02.28
Gromova Elena.................. PS01.05
Gryglewski Gregor........ PS01.64, PS02.19
Gunduz-Bruce Handan........ PS01.08, PS01.11
Gutierrez Sonia.................. PS01.48

H
Hagsäter Melker.................. PS01.62
Hahn Andreas.................. PS01.64, PS02.19
Haiba Amr.......................... PS02.29
Hajek Tomas.................. PS02.62
Halaris Angelos........ PS02.35
Handschuh Patricia................ PS01.64
Han You Jung................ PS01.55
Ha Seungyoon.................. PS02.07
Haslacher Helmuth................ S01.28
Ha Tae Hyon.................. PS01.37
Hendrick Jospeh............... PS01.14
Heo Jung Yoon................ PS01.36
Herrmann Luisa............... PS01.16, PS01.17
Hickman Robert................ PS01.06
Hieronymus Fredrik........ PS01.30, PS02.20
Hill Andrew.................. PS02.49
Hirata Nao.................. PS02.56
<table>
<thead>
<tr>
<th>Name</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Knytl Pavel</td>
<td>PS02.62</td>
</tr>
<tr>
<td>Kocsis Bernat</td>
<td>PS02.45, PS02.46</td>
</tr>
<tr>
<td>Kohda Fumio</td>
<td>PS02.38</td>
</tr>
<tr>
<td>Köhler-Forsberg Ole</td>
<td>PS02.20, PS02.32, PS02.33</td>
</tr>
<tr>
<td>Koistinaho Jari</td>
<td>PS02.49</td>
</tr>
<tr>
<td>Kokkali Anastasia</td>
<td>PS02.51</td>
</tr>
<tr>
<td>Kokras Nikolaos</td>
<td>PS02.60</td>
</tr>
<tr>
<td>Kolenic Marian</td>
<td>PS02.62</td>
</tr>
<tr>
<td>Koller Romina</td>
<td>PS01.28</td>
</tr>
<tr>
<td>Komelkova Mariya</td>
<td>PS01.49, PS01.58, PS01.60</td>
</tr>
<tr>
<td>Komorowski Arkadiusz</td>
<td>PS01.18</td>
</tr>
<tr>
<td>Koschkina Aleksandra</td>
<td>PS01.21</td>
</tr>
<tr>
<td>Koschkina Alexandra</td>
<td>PS01.22</td>
</tr>
<tr>
<td>Koskuvi Marja</td>
<td>PS02.49</td>
</tr>
<tr>
<td>Kosutova Petra</td>
<td>PS02.28</td>
</tr>
<tr>
<td>Kotorii Nozomu</td>
<td>PS01.42</td>
</tr>
<tr>
<td>Kotoula Vasileia</td>
<td>PS02.26</td>
</tr>
<tr>
<td>Kouhkamari Mahsa</td>
<td>PS02.47, PS02.48</td>
</tr>
<tr>
<td>Kouhenis Grigoris</td>
<td>PS02.57, PS02.60</td>
</tr>
<tr>
<td>Kouniakis Fillipos</td>
<td>PS02.60</td>
</tr>
<tr>
<td>Kraus Christoph</td>
<td>WS01.1</td>
</tr>
<tr>
<td>Krebs Michael</td>
<td>PS02.58</td>
</tr>
<tr>
<td>Krivosova Michael</td>
<td>PS02.28</td>
</tr>
<tr>
<td>Krogh-Nielsen Lene</td>
<td>PS01.24</td>
</tr>
<tr>
<td>Kryczyk Agata</td>
<td>PS01.32</td>
</tr>
<tr>
<td>Krylova Marina</td>
<td>PS01.17</td>
</tr>
<tr>
<td>Krymov Eldar</td>
<td>PS01.05</td>
</tr>
<tr>
<td>Krystal Andrew</td>
<td>S05.1</td>
</tr>
<tr>
<td>Krystal John</td>
<td>KL01.1, YSF01.1</td>
</tr>
<tr>
<td>Kühnel Anne</td>
<td>PS01.17</td>
</tr>
<tr>
<td>Ku Min Jeong</td>
<td>PS02.09</td>
</tr>
<tr>
<td>Kuriyama Kenichi</td>
<td>PS01.42</td>
</tr>
<tr>
<td>Kuroiwa Takashi</td>
<td>PS02.38</td>
</tr>
<tr>
<td>Kunisr Patrik</td>
<td>PS02.28</td>
</tr>
<tr>
<td>Kwak Myung Ji</td>
<td>PS02.04, PS02.09</td>
</tr>
<tr>
<td>Kwon Young Nam</td>
<td>PS01.29</td>
</tr>
<tr>
<td>Kyriakos Dimitrios</td>
<td>PS02.57</td>
</tr>
<tr>
<td>Kyriakou Christina</td>
<td>PS01.13, PS01.56</td>
</tr>
<tr>
<td>Kyriakou Sophia</td>
<td>PS01.56</td>
</tr>
<tr>
<td>Larsson Henrik</td>
<td>PS02.10</td>
</tr>
<tr>
<td>Lasser Robert</td>
<td>PS01.08</td>
</tr>
<tr>
<td>Lazarus Hillard</td>
<td>PS02.25</td>
</tr>
<tr>
<td>Lecca Bernadette</td>
<td>PS01.06</td>
</tr>
<tr>
<td>Lee Baer</td>
<td>PS01.36</td>
</tr>
<tr>
<td>Lee Dongyun</td>
<td>PS01.54, PS01.55</td>
</tr>
<tr>
<td>Lee Hyun Jeong</td>
<td>PS02.37</td>
</tr>
<tr>
<td>Lee I-Chun</td>
<td>PS02.69</td>
</tr>
<tr>
<td>Lee Jae Yeon</td>
<td>PS01.29</td>
</tr>
<tr>
<td>Lee Jung</td>
<td>S01.47, PS02.08</td>
</tr>
<tr>
<td>Lee Kanguk</td>
<td>PS02.03</td>
</tr>
<tr>
<td>Lee Kyoung-Uk</td>
<td>PS01.23</td>
</tr>
<tr>
<td>Lee Kyung Kyu</td>
<td>PS02.02</td>
</tr>
<tr>
<td>Lee Sang-Yoon</td>
<td>PS01.15</td>
</tr>
<tr>
<td>Lee Seonah</td>
<td>PS01.36</td>
</tr>
<tr>
<td>Lee Soo Yeon</td>
<td>PS01.37</td>
</tr>
<tr>
<td>Lee Un Joo</td>
<td>PS01.52</td>
</tr>
<tr>
<td>Lee Yoonji Irene</td>
<td>PS01.29</td>
</tr>
<tr>
<td>Lee Yunna</td>
<td>PS02.37</td>
</tr>
<tr>
<td>Leggio Lorenzo</td>
<td>PS01.50</td>
</tr>
<tr>
<td>Lehr Lisa</td>
<td>PS02.27</td>
</tr>
<tr>
<td>Lehtonen Sarka</td>
<td>PS02.49</td>
</tr>
<tr>
<td>Lenniger Carly</td>
<td>PS02.12</td>
</tr>
<tr>
<td>León-Ortiz Pablo</td>
<td>PS02.53</td>
</tr>
<tr>
<td>Leucht Stefan</td>
<td>PS01.41</td>
</tr>
<tr>
<td>Li Ella</td>
<td>PS01.11</td>
</tr>
<tr>
<td>Li Hahong</td>
<td>PS01.09, PS01.11</td>
</tr>
<tr>
<td>Li Meng</td>
<td>PS01.16, PS01.25</td>
</tr>
<tr>
<td>Lin Shih-Ku</td>
<td>S02.3</td>
</tr>
<tr>
<td>Li Sigui</td>
<td>PS01.08, PS01.39</td>
</tr>
<tr>
<td>Lisinski Alexander</td>
<td>PS01.30</td>
</tr>
<tr>
<td>Llorca Pierre Michel</td>
<td>S05.2</td>
</tr>
<tr>
<td>Lönnqvist Jouko</td>
<td>PS02.49</td>
</tr>
<tr>
<td>López José</td>
<td>PS02.64</td>
</tr>
<tr>
<td>Ludwig Birgit</td>
<td>PS01.28</td>
</tr>
<tr>
<td>Lürzer Sabine</td>
<td>PS01.19</td>
</tr>
<tr>
<td>Lyoo In Kyoon</td>
<td>PS02.15, PS02.16</td>
</tr>
</tbody>
</table>

**M**

<table>
<thead>
<tr>
<th>Name</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Majuri Joonas</td>
<td>PS01.46</td>
</tr>
<tr>
<td>Mano Tomoyuki</td>
<td>PS01.68</td>
</tr>
<tr>
<td>Mao Xiangling</td>
<td>PS02.53</td>
</tr>
<tr>
<td>Marcus Monica</td>
<td>PS01.14</td>
</tr>
<tr>
<td>Martin Angel</td>
<td>PS02.64</td>
</tr>
<tr>
<td>Martin-Pinto Tomás</td>
<td>PS02.64</td>
</tr>
<tr>
<td>Martis Lena-Sophie</td>
<td>PS02.17</td>
</tr>
<tr>
<td>Mason Barbara</td>
<td>PS01.67</td>
</tr>
<tr>
<td>Mates Sharon</td>
<td>PS01.14</td>
</tr>
<tr>
<td>Mccal William</td>
<td>PS02.31, PS02.36</td>
</tr>
</tbody>
</table>
Author Index

Mccloud Laryssa .................................. PS02.31
McCracken James ................................ PS02.13
Mcguire Philip .................................. PS02.67
Meana J. Javier .................................. PS02.59
Mehtālā Juha ...................................... PS02.43
Mehta Mitul ...................................... PS02.26
Mekky Jaida ...................................... PS01.43, PS01.63
Meltzer-Brody Samantha .................... PS01.09
Mendlewicz Julian ............................. PS01.70, PS02.34
Michenthaler Paul ............................ PS01.64
Mills Jessica ..................................... PS01.26
Mimura Masaru .................................. PS01.10
Mischoulon David ............................ PS01.33, PS01.34, PS01.35, PS01.36, PS02.14
Mishima Kazuo .................................. PS01.42
Misionzhnik Yuli ................................ PS02.71
Miszatka Paulina ............................... PS01.32
Mitschek Marleen Mignon .................. PS01.28
Mitterhauser Markus ...................... PS01.64, PS02.19
Miura Kengo ..................................... PS02.38
Miyakawa Tsuyoshi ............................ PS02.56
Mofleh Rola ...................................... PS02.46
Mokry Juraj ...................................... PS02.28
Möller Hans-Jürgen ...................... S06.3, WS02.3
Molokhia Tarek .............................. PS01.43, PS01.63
Montejo Angel Luis .......................... PS02.64
Montgomery Stuart ......................... PS01.70, PS02.34
Moore Allamar ................................. PS01.50
Mora Ricardo .................................. PS02.53
Mougiakos Theodoros ....................... PS02.60
Mullan Judy ..................................... PS02.47, PS02.48
Mumm Birgitte ................................. PS01.38
Mumm Birgitte Hvid ......................... PS02.17
Murakami Akira ............................... PS02.56
Murano Tomoyuki ............................ PS02.56
Murck Harald ................................. PS01.39, PS02.27
Muszyńska Bożena .......................... PS01.32
Myung Woojae ................................. PS01.37, PS02.39

N
Na Eun Jin ........................ PS01.33, PS01.34, PS01.35, PS01.52
Nakajima Ryuichi ............................. PS02.56
Nakao Akito ..................................... PS02.56
Nakatsu Keigo .................................. PS02.61
Nanni Melanni ................................. PS01.16
Nash Abigail .................................. PS01.03
Náslund Jakob ................................. PS01.62
Nics Lukas ..................................... PS02.58
Nierenberg Andrew ......................... PS02.32

O
Odagaki Yuji .................................. PS02.59
Ohki Takehumi ............................... PS01.02
Oikonomou Achilleas ....................... PS01.60
Ojansuu Ilkka ................................ PS02.49
Okajima Isao .................................. PS01.42
Okasha Tarek ................................. KL02.1
Ondrejka Igor .................................. PS02.28
Ono Hiroaki .................................... PS01.68
Opoka Wlodzimierz ......................... PS01.32
Østergaard Søren Dinesen ................. PS02.20, PS02.33
Ota Marie ....................................... PS01.27, PS02.06
Owen Randy .................................. PS02.44

P
Pagkalos Georgios .......................... PS02.57
Pai Nagesh ...................................... PS02.47, PS02.48
Palucha-Powiewiera Agnieszka ............ PS01.31
Panov Dmitriy ............................... PS01.05
Papadopoulos Andreas ..................... MTE02.2b
Papagavriil Eirini ............................ PS02.57
Papakostas George ......................... PS01.34, PS01.35, PS01.36, PS02.14
Paraschakis Antonios ...................... PS02.50
Park C. Hyung Keun ....................... PS02.37
Park Hyungseo ............................... PS01.47, PS02.08
Park Jong Woo ............................... PS02.04
Park Joonhyuk ............................... PS01.53
Park Mi Jin ................................. PS01.52
Park Sonmi .................................. PS01.09
Paskavitz James ............................ PS01.39
Pastiadias Konstantinos ................... S06.1
Patriki Fani .................................... PS02.60
Paul Steven .................................. PS01.11
Petersen Liselotte ............................ PS02.20
Peterson Meghan ......................... PS02.29
Pettersson Robert .......................... PS01.62
Pfafl Sarah .................................. PS02.58
Philippe Cecile .............................. PS02.19
Piachas Athanasios ....................... PS02.57
Pichler Verena ........................................... PS02.19, PS02.58
Pityk Olena ................................................ PS01.65
Pochwat Bartłomiej .......................... PS01.32
Podkowa Karolina ........................... PS01.31
Poguzhelskaya Ekaterina ............... PS02.49
Praschak-Rieder Nicole .................. PS02.58
Prieto Nieves ........................................ PS02.64
Psarra Vasiliki .............................. PS02.60
Puttenen Katja ................................ PS02.49

Q
Quatrano Susan ................................ PS01.06
Quinn Patrick D. .............................. PS02.10
Quirk Michael ................................ PS01.39

R
Rabbani Habib A ................................ PS01.45
Rady Ahmed ................................ PS01.43, PS01.63
Rafalo-Ulińska Anna .................... PS01.31, PS01.32
Ramos-Quiroga Josep Antoni .......... PS01.48
Rask-Pedersen Eva ......................... PS01.24
Ravilla Dheeraj ............................. PS02.31
Renka Jirka ........................................ PS02.62
Reyes-Madrigal Francisco .......... PS02.53, PS02.37
Rhee Sang Jin ................................ PS02.37
Richarte Vanesa .............................. PS01.48
Riesenber Robert .......................... PS01.09, PS01.11
Robbins Trevor W. ........................ PS02.66
Ropacki Michael .......................... PS01.48
Rosenquist Peter .......................... PS02.31, PS02.36
Rothschild Anthony ................ PS01.11
Rubinow David ......................... PS01.09, PS01.11
Ryu Vin ................................ PS02.21

S
Sackheim Harold ............................. PS02.36
Sadek Sameh ................................ PS02.29
Sahakian Barbara J. .................... PS01.67, PS02.66
Sahlem Greg ................................ PS02.36
Saido Takaomi C. ......................... PS01.68
Saito Takashi ........................ PS01.68
Sakurai Noriko ................................ PS01.02, PS01.12
Salamone Salvatore ................ PS02.67
Salanti Georgia ............................. S06.2
Samara Myrto ................................ PS01.41
Samaras Konstantinos ................. S02.57, PS02.60
Samsom James .......................... PS02.52
Sanahuja Muñoz Clara ............... PS01.57, PS02.18
Sanak Marek ................................ PS01.20
Sánchez-Iglesias Santiago .......... PS02.64
Sankar Anjali............................ PS01.06
Sankoh Abdul ........................... PS01.08, PS01.11, PS01.39
Sarapultsev Alexey ................ PS01.49
Satlin Andrew ............................ PS01.14
Sato Ayaka .................................. PS01.27, PS02.06
Sato Goro ................................ PS02.61
Sauerzapf Ulrich ........................... PS02.58
Savulich George J. ........................ PS01.67, PS02.66
Sawanobori Youseuke ................. PS01.27, PS02.06
Scherer Thomas ........................ PS02.58
Schosser Alexandra .................. PS01.28
Schultz Myron .......................... PS01.16, PS01.17
Sebela Antonin ........................ PS02.62
Seifritz Erich .......................... WSO4.1
Seiger René ................................ PS01.64, PS02.19
Sekaninova Nikola ........................ PS02.28
Sekiguchi Kiyohi ........................ PS02.38
Selamoglu Ayla ........................ PS01.67
Serretti Alessandro ................ PS01.70, PS02.34, S01.2
Setta-Kaffetzi Niovi ................... PS02.57, PS02.60
Shannon Weickert Cynthia .......... PS02.42
Shikhov Sergei ........................ PS01.71, PS02.71
Shimizu Chika ................................ PS01.68
Shimura Akioshi ................. PS01.42
Shin Joon Sung ......................... PS01.29
Shi Wei-Xing ........................ PS02.05
Short Baron ........................ PS02.36
Shungu Dikoma .......................... PS02.53
Silberbauer Leo ........................ PS01.19
Silber Christopher ................ PS01.08, PS01.11, PS01.39
Silverman Wendy .................. PS01.06
Siodlak Dominika ................ PS01.32
Siva Sinthuja ........................ PS02.47, PS02.48
Skandali Nikola ........................ PS01.46
Smaga-Mašlanka Irena .............. PS01.20
Smolina Natalia ................ PS02.71
Snyder Gretchen ........................ PS01.14
Song Jaewon ........................ PS01.47, PS02.07
Son Young-Don ................ PS01.15
Sotiriadou Konstantina .............. PS02.57
Souery Daniel ......................... MTE02.2a, PS01.70, PS02.34
Spaniel Filip ........................ PS02.62
Spencer Linda .......................... PS01.06
Stankovic Srdjan ........................ PS02.44
Stergiou Theofillos .................. PS02.57
Stone James ........................ PS02.26
Storvik Markus ................ PS02.49
Strelkova Irina ................ PS02.71
<table>
<thead>
<tr>
<th>Author Index</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>V</strong></td>
</tr>
<tr>
<td>Valverde Marta .................................. PS01.48</td>
</tr>
<tr>
<td>Vanover Kim ........................................ PS01.14</td>
</tr>
<tr>
<td>Varoglu Mustafa .................................. PS01.39</td>
</tr>
<tr>
<td>Vattulainen Pia .................................... PS02.43</td>
</tr>
<tr>
<td>Vaurio Olli .......................................... PS02.49</td>
</tr>
<tr>
<td>Velosa Ana .......................................... PS02.11</td>
</tr>
<tr>
<td>Voon Valerie ........................................ PS01.46</td>
</tr>
<tr>
<td>Voskarides Konstantinos .......................... PS01.13</td>
</tr>
<tr>
<td>Voulgaraki A ......................................... PS02.57</td>
</tr>
<tr>
<td>Vraka Chrysoula ...................................... PS01.64</td>
</tr>
<tr>
<td>Vrysis Lazaros ...................................... S05.1</td>
</tr>
<tr>
<td><strong>U</strong></td>
</tr>
<tr>
<td>Ueda Hiroki R ...................................... PS01.68</td>
</tr>
<tr>
<td>Umeda Satoshi ....................................... PS01.10</td>
</tr>
<tr>
<td>Uno Hiromitsu ........................................ PS01.27, PS02.06</td>
</tr>
<tr>
<td>Unterholzer Jakob .................................. PS01.64, PS02.19</td>
</tr>
<tr>
<td>Utsumi Tomohiro .................................... PS01.42</td>
</tr>
<tr>
<td>Uzbekova Dinara ..................................... PS02.71</td>
</tr>
<tr>
<td>Uzbekov Marat ....................................... PS01.71, PS02.71</td>
</tr>
<tr>
<td><strong>T</strong></td>
</tr>
<tr>
<td>Tachibana Tomoyuki ................................ PS01.27, PS02.06</td>
</tr>
<tr>
<td>Tagawa Minami ....................................... PS01.02, PS01.12</td>
</tr>
<tr>
<td>Taipale Heidi ........................................ PS02.43</td>
</tr>
<tr>
<td>Takaesu Yoshikazu .................................. PS01.42, PS02.23</td>
</tr>
<tr>
<td>Takashio Osamu ...................................... PS01.27, PS02.06</td>
</tr>
<tr>
<td>Takei Yuichi ......................................... PS01.02, PS01.10, PS01.12</td>
</tr>
<tr>
<td>Tamminga Carol ...................................... S02.1</td>
</tr>
<tr>
<td>Tanskanen Antti ...................................... PS02.43</td>
</tr>
<tr>
<td>Tar Tibor ............................................. PS01.16, PS01.17</td>
</tr>
<tr>
<td>Taylor David ......................................... PS02.67, SP02.1</td>
</tr>
<tr>
<td>Terman Sebastian ..................................... PS02.49</td>
</tr>
<tr>
<td>Thomason Moriah ...................................... PS02.30</td>
</tr>
<tr>
<td>Thomas Susan .......................................... PS01.26</td>
</tr>
<tr>
<td>Tiibonen Jari ........................................ PS02.43, PS02.49</td>
</tr>
<tr>
<td>Titulaer Joep ........................................ PS01.14</td>
</tr>
<tr>
<td>Tohka Jussi ........................................... PS02.49</td>
</tr>
<tr>
<td>Tomiyama Keichiro .................................. PS02.38</td>
</tr>
<tr>
<td>Tonhajzerova Ingrid .................................. PS02.28</td>
</tr>
<tr>
<td>Touloumis Charalampos ................................ S03.1</td>
</tr>
<tr>
<td>Tsaltas Christos ..................................... PS02.60</td>
</tr>
<tr>
<td>Tsapakis Eva-Maria ................................... PS02.57, PS02.60</td>
</tr>
<tr>
<td>Tseylikman Olga ...................................... PS01.49, PS01.58, PS01.60</td>
</tr>
<tr>
<td>Tseylikman Vadim .................................... PS01.49, PS01.58, PS01.60</td>
</tr>
<tr>
<td>Tsopelas Christos .................................... S03.2</td>
</tr>
<tr>
<td>Tuboi Takashi ........................................ PS02.23</td>
</tr>
<tr>
<td>Tzeferakos Georgios .................................. PS02.57, S03.3</td>
</tr>
<tr>
<td><strong>W</strong></td>
</tr>
<tr>
<td>Wadhwa Jenny ........................................ PS01.06</td>
</tr>
<tr>
<td>Wadsak Wolfgang ..................................... PS01.64, PS02.19, PS02.58</td>
</tr>
<tr>
<td>Wakatabe Hirofumi .................................. PS02.38</td>
</tr>
<tr>
<td>Walter Martin ........................................ PS01.16, PS01.17</td>
</tr>
<tr>
<td>Wapenaar Robert ..................................... PS02.57</td>
</tr>
<tr>
<td>Watanabe Koichiro ................................... PS02.23</td>
</tr>
<tr>
<td>Watanabe Norio ....................................... PS01.42</td>
</tr>
<tr>
<td>Webster Irena ........................................ PS01.39</td>
</tr>
<tr>
<td>Webster Maree J ...................................... PS02.42</td>
</tr>
<tr>
<td>Wegener Gregers ...................................... PS02.24</td>
</tr>
<tr>
<td>Weidenauer Ana ....................................... PS02.58</td>
</tr>
<tr>
<td>Weisssleder Christin ................................ PS02.42</td>
</tr>
<tr>
<td>Wennogle Lawrence .................................. PS01.14</td>
</tr>
<tr>
<td>Wiborg Ove ............................................ PS02.17</td>
</tr>
<tr>
<td>Wickham Katie ........................................ PS01.51</td>
</tr>
<tr>
<td>Willeit Matthaus ..................................... PS02.58</td>
</tr>
<tr>
<td>Wilnerzon Thorn Carolina ......................... PS02.45</td>
</tr>
<tr>
<td>Winkler Dietmar ...................................... PS01.18, PS01.19</td>
</tr>
<tr>
<td>Winkler-Pjrek Edda .................................. PS01.18, PS01.19</td>
</tr>
<tr>
<td>Wong Albert .......................................... PS02.52</td>
</tr>
<tr>
<td>Wong Felix ............................................. PS02.52</td>
</tr>
<tr>
<td>Won Hong-Hee ......................................... PS02.39</td>
</tr>
<tr>
<td>Woo T. Wilson ........................................ PS02.68</td>
</tr>
<tr>
<td>Wydra Karolina ...................................... PS01.20</td>
</tr>
<tr>
<td><strong>X</strong></td>
</tr>
<tr>
<td>Xi Zheng-Xiong ...................................... PS01.50</td>
</tr>
<tr>
<td>Xomalis Dimitrios .................................... PS02.60</td>
</tr>
<tr>
<td>Xu Mengyi ............................................. PS02.52</td>
</tr>
<tr>
<td>Xu Qingqing .......................................... PS02.22, PS02.55</td>
</tr>
<tr>
<td>Xu Shijie ............................................... PS01.66</td>
</tr>
<tr>
<td>Name</td>
</tr>
<tr>
<td>-----------------------------</td>
</tr>
<tr>
<td>Yada Hiroki</td>
</tr>
<tr>
<td>Yamada Mari</td>
</tr>
<tr>
<td>Yamamoto Jun</td>
</tr>
<tr>
<td>Yamashita Hidehisa</td>
</tr>
<tr>
<td>Yanagihara Haruka</td>
</tr>
<tr>
<td>Yang Chanmo</td>
</tr>
<tr>
<td>Yang Hyunju</td>
</tr>
<tr>
<td>Yang Jinho</td>
</tr>
<tr>
<td>Yoo Ji Hyun</td>
</tr>
<tr>
<td>Yook Dong Yeun</td>
</tr>
<tr>
<td>Yoon Narae</td>
</tr>
<tr>
<td>Yoon Sujung</td>
</tr>
<tr>
<td>Yoshida Tomohiro</td>
</tr>
<tr>
<td>Youakim James</td>
</tr>
<tr>
<td>Youssef Nagy</td>
</tr>
<tr>
<td>You Zhi-Bing</td>
</tr>
<tr>
<td>Yu Han Young</td>
</tr>
<tr>
<td>Yun Ji-Ae</td>
</tr>
<tr>
<td>Yu Shunying</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Name</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zarate Carlos</td>
<td>S01.3</td>
</tr>
<tr>
<td>Zavorotnyy Maxim</td>
<td>PS02.27</td>
</tr>
<tr>
<td>Zhang Bin</td>
<td>PS01.25</td>
</tr>
<tr>
<td>Zhang Lei</td>
<td>PS01.14</td>
</tr>
<tr>
<td>Zhan Yanni</td>
<td>PS01.25</td>
</tr>
<tr>
<td>Zhou Yanling</td>
<td>PS01.25</td>
</tr>
<tr>
<td>Zittis Marios</td>
<td>PS02.57</td>
</tr>
<tr>
<td>Zohar Joseph</td>
<td>PS01.70, PS02.34, YSF01.2</td>
</tr>
<tr>
<td>Zorumski Charles</td>
<td>PS01.11</td>
</tr>
</tbody>
</table>
## Future CINP Congresses

<table>
<thead>
<tr>
<th>Date</th>
<th>Location</th>
<th>Congress Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>25 - 28 June, 2020</td>
<td>Taipei, Taiwan</td>
<td>32(^{\text{nd}}) CINP World Congress</td>
</tr>
<tr>
<td>4 - 7 July, 2021</td>
<td>Montreal, Canada</td>
<td>33(^{\text{rd}}) CINP World Congress</td>
</tr>
<tr>
<td>26 - 29 June, 2022</td>
<td>Melbourne, Australia</td>
<td>34(^{\text{th}}) CINP World Congress</td>
</tr>
<tr>
<td>3 - 6 June, 2023</td>
<td>Helsinki, Finland</td>
<td>35(^{\text{th}}) CINP World Congress</td>
</tr>
<tr>
<td>25 - 28 June, 2024</td>
<td>Tokyo, Japan</td>
<td>36(^{\text{th}}) CINP World Congress</td>
</tr>
</tbody>
</table>
Save the Date

2020 CINP World Congress
25-28 June 2020 Taipei, Taiwan

THE INTERNATIONAL COLLEGE OF NEUROPSYCHOPHARMACOLOGY